Tokushima University / Educator and Researcher Directory --- Ogino, Hirokazu

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Thi Na Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara and Yasuhiko Nishioka : Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies., Thoracic Cancer, Vol.15, No.5, 369-378, 2024. (Summary) Our findings indicate that fluoropyrimidine can be an immunologically optimal partner of ICIs through the induction of ICD for thoracic malignancies. (Keyword) Humans / Animals / Mice / Carcinoma, Non-Small-Cell Lung / Immune Checkpoint Inhibitors / CD8-Positive T-Lymphocytes / Platinum / Immunogenic Cell Death / Lung Neoplasms / Pemetrexed / Antimetabolites / Cell Line, Tumor / Taxoids / Fluorouracil / Adenosine Triphosphate / Tumor Microenvironment (Tokushima University Institutional Repository) ● Metadata: 119383 (Link to Publication Site) ● Publication site (DOI): 10.1111/1759-7714.15200 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38146645 ● Search Scopus @ Elsevier (PMID): 38146645 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.15200 (Tokushima University Institutional Repository: 119383, DOI: 10.1111/1759-7714.15200, PubMed: 38146645)
2.	Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Thi Na Nguyen, Hiroshi Nokihara, Seidai Satou, Tsutomu Shinohara, Masaki Hanibuchi, Shinji Abe, K Mika Kaneko, Yukinari Kato and Yasuhiko Nishioka : Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells., Cancer Science, Vol.115, No.2, 357-368, 2024. (Summary) -f enhanced the antitumor effects of CTLA-4 blockade. Combination therapy with anti-PDPN Ab and anti-CTLA-4 Ab increased tumor-infiltrating natural killer (NK) cells. The depletion of NK cells inhibited the synergistic effects of PMab-1-mG (Keyword) Rats / Mice / Animals / Cricetinae / Mesothelioma, Malignant / Antibodies, Monoclonal / CTLA-4 Antigen / Membrane Glycoproteins / Mesothelioma / Killer Cells, Natural / Cricetulus / CHO Cells (Tokushima University Institutional Repository) ● Metadata: 119228 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.16046 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38148492 ● Search Scopus @ Elsevier (PMID): 38148492 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.16046 (Tokushima University Institutional Repository: 119228, DOI: 10.1111/cas.16046, PubMed: 38148492)
3.	Eiji Takeuchi, Hirokazu Ogino, Kensuke Kondo, Yoshio Okano, Seiya Ichihara, Michihiro Kunishige, Naoki Kadota, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors., Thoracic Cancer, Vol.15, No.3, 248-257, 2024. (Summary) An increased relative eosinophil count (REC) has potential as a predictive biomarker for a beneficial clinical response and outcome to cancer immunotherapies. Therefore, the present study investigated the impact of an increased posttreatment REC on the prognosis of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). We retrospectively reviewed all 151 patients diagnosed with NSCLC and treated with ICI monotherapy and blood test data between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University. A total of 151 patients with a mean age of 69 years were included. REC after 4 weeks of initial ICI monotherapy was higher than pretreatment REC in 87 patients but not in 64. REC after 4 weeks of the ICI treatment with and without an increased REC were 4.4 and 1.8%, respectively (p < 0.001). Disease control rates (DCR) were significantly higher in patients with than in those without an increased REC (84% vs. 47%, p < 0.001). The median overall survival (OS) of lung cancer patients with or without an increased REC were 674 and 234 days, respectively. A Kaplan-Meier univariate analysis revealed a significant difference in OS between the two groups (p < 0.001). A Cox proportional regression analysis identified an increased REC as an independent predictor of OS (p = 0.003). ICI-treated NSCLC patients with an increased REC after 4 weeks of treatment had a better DCR and prognosis than the other patients examined. (Keyword) Humans / Aged / Carcinoma, Non-Small-Cell Lung / Immune Checkpoint Inhibitors / Lung Neoplasms / Eosinophils / Retrospective Studies / Biomarkers (Tokushima University Institutional Repository) ● Metadata: 119414 (Link to Publication Site) ● Publication site (DOI): 10.1111/1759-7714.15191 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38087769 ● CiNii @ National Institute of Informatics (CRID): 1873116917870314752 ● Summary page in Scopus @ Elsevier: 2-s2.0-85179299821 (Tokushima University Institutional Repository: 119414, DOI: 10.1111/1759-7714.15191, PubMed: 38087769, CiNii: 1873116917870314752, Elsevier: Scopus)
4.	Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Atsushi Mitsuhashi, Kenji Otsuka, Seidai Satou, Hisatsugu Goto, Hiroto Yoneda, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer., Thoracic Cancer, Vol.14, No.32, 3232-3239, 2023. (Summary) Combination chemotherapy with PEM plus Bev in elderly patients with previously untreated advanced non-squamous NSCLC exhibited favorable antitumor activity and tolerability, suggesting that a combination of PEM plus Bev might be a promising treatment option for this population. (Keyword) Humans / Aged / Aged, 80 and over / Carcinoma, Non-Small-Cell Lung / Pemetrexed / Bevacizumab / Lung Neoplasms / Treatment Outcome / Antineoplastic Combined Chemotherapy Protocols (Tokushima University Institutional Repository) ● Metadata: 119483 (Link to Publication Site) ● Publication site (DOI): 10.1111/1759-7714.15115 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37718463 ● Search Scopus @ Elsevier (PMID): 37718463 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.15115 (Tokushima University Institutional Repository: 119483, DOI: 10.1111/1759-7714.15115, PubMed: 37718463)
5.	Eiji Takeuchi, Kensuke Kondo, Yoshio Okano, Seiya Ichihara, Michihiro Kunishige, Naoki Kadota, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors., Thoracic Cancer, Vol.14, No.30, 3042-3050, 2023. (Summary) We retrospectively reviewed all patients diagnosed with NSCLC and treated with ICI monotherapy between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University. (Keyword) Humans / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Immune Checkpoint Inhibitors / Eosinophils / Retrospective Studies / Biomarkers (Tokushima University Institutional Repository) ● Metadata: 119484 (Link to Publication Site) ● Publication site (DOI): 10.1111/1759-7714.15100 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37669914 ● Search Scopus @ Elsevier (PMID): 37669914 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.15100 (Tokushima University Institutional Repository: 119484, DOI: 10.1111/1759-7714.15100, PubMed: 37669914)
6.	Hiroki Takahashi, Hirokazu Ogino, Hiroki Bando, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma., Respiratory Medicine Case Reports, Vol.45, 101893, 2023. (Tokushima University Institutional Repository) ● Metadata: 119403 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.rmcr.2023.101893 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37485237 ● Search Scopus @ Elsevier (PMID): 37485237 ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2023.101893 (Tokushima University Institutional Repository: 119403, DOI: 10.1016/j.rmcr.2023.101893, PubMed: 37485237)
7.	Atsushi Mitsuhashi, Kazuya Koyama, Hirokazu Ogino, Tania Afroj, Thi Na Nguyen, Hiroto Yoneda, Kenji Otsuka, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara, Masaki Hanibuchi, Hiromitsu Takizawa, Tsutomu Shinohara and Yasuhiko Nishioka : Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade., Cell Reports, Vol.42, No.3, 112162, 2023. (Summary) fibrocytes do not. Tumor-infiltrating fibrocytes acquire myofibroblast-like phenotypes through transforming growth factor β (TGF-β)/small mothers against decapentaplegic (SMAD) signaling. Thus, TGF-βR/SMAD inhibitor enhances the antitumor effects of dual VEGF and PD-L1 blockade by regulating fibrocyte differentiation. Fibrocytes are highlighted as regulators of the response to programmed death 1 (PD-1)/PD-L1 blockade. (Keyword) Humans / vascular endothelial growth factor / Neoplasms / B7-H1 Antigen / immunotherapy / Tumor Microenvironment (Tokushima University Institutional Repository) ● Metadata: 118888 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.celrep.2023.112162 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36870329 ● Search Scopus @ Elsevier (PMID): 36870329 ● Search Scopus @ Elsevier (DOI): 10.1016/j.celrep.2023.112162 (Tokushima University Institutional Repository: 118888, DOI: 10.1016/j.celrep.2023.112162, PubMed: 36870329)
8.	T Na Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Tania Afroj, Seidai Satou, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor., Cancer Science, Vol.114, No.2, 384-398, 2023. (Summary) Myeloid-derived suppressor cells (MDSCs) have been known to play a pivotal role in the induction of immune tolerance, which limits the benefits of immune checkpoint inhibitors (ICIs). Recent studies revealed that several chemotherapeutic agents decreased tumor-infiltrating MDSCs. Therefore, combination therapy with cytotoxic chemotherapeutic agents and ICIs was approved for first-line treatment for lung cancer. However, the impact of chemotherapeutic agents on MDSCs and an optimal partner of ICIs has not been fully investigated in thoracic tumors, including lung cancer and malignant pleural mesothelioma. In the present study, we found that treatment with 5-FU and its oral formulation, S-1, suppressed tumor progression and inhibited the accumulation of MDSCs in thoracic tumor-bearing mice. Tumor-infiltrating T cells and dendritic cells were significantly expanded in S-1-treated mice. 5-FU suppressed the ability of tumor cells to recruit MDSCs, while it did not suppress the survival and differentiation of mouse MDSCs in vitro. We also revealed that 5-FU or S-1 significantly downregulated the expression of tumor-derived Bv8 and S100A8. The knockdown of Bv8 or S100A8 in tumor cells suppressed tumor growth and MDSC recruitment in vivo. Furthermore, in comparison with pemetrexed, administration of S-1 improved the synergistic therapeutic efficacy of anti-PD-1 antibodies with or without carboplatin. Our findings revealed a novel mechanism wherein S-1 primed a favorable tumor microenvironment to provide the rationale for combination therapy with S-1 and ICIs as the optimal therapy for thoracic cancer. (Keyword) Mice / Animals / Myeloid-Derived Suppressor Cells / Calgranulin A / T lymphocytes / Thoracic Neoplasms / Lung Neoplasms / Tumor Microenvironment / Cell Line, Tumor (Tokushima University Institutional Repository) ● Metadata: 118295 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.15620 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36285504 ● Search Scopus @ Elsevier (PMID): 36285504 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15620 (Tokushima University Institutional Repository: 118295, DOI: 10.1111/cas.15620, PubMed: 36285504)
9.	Seiya Ichihara, Hirokazu Ogino, Hiroto Yoneda, Keiko Haji, Kozo Kagawa, Kojin Murakami, Masato Mima, Yu Aoi, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody., Respiratory Medicine Case Reports, Vol.41, 101797, 2023. (Summary) A man with non-small-cell lung cancer who was negative for anti-nuclear antibodies was admitted for dyspnea after immune checkpoint inhibitor (ICI) administration. Computed tomography (CT) showed complexed radiologic features, including subpleural and basal predominant reticular shadow with cystic structures and peribronchovascular consolidation. Although we treated him with high-dose steroid under a diagnosis of ICI-related pneumonitis, he developed acute exacerbation of pneumonitis with progressive fibrosis and volume loss. A re-evaluation identified anti-aminoacyl-tRNA synthetase antibody in the serum collected before ICI administration. This case highlights the importance of re-evaluating pre-existing autoimmune disorders in patients who develop ICI-related pneumonitis with atypical radiologic features. (Tokushima University Institutional Repository) ● Metadata: 119054 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.rmcr.2022.101797 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36583061 ● Search Scopus @ Elsevier (PMID): 36583061 ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2022.101797 (Tokushima University Institutional Repository: 119054, DOI: 10.1016/j.rmcr.2022.101797, PubMed: 36583061)
10.	Muneo Numasaki, Koyu Ito, Kiyoshi Takagi, Kengo Nagashima, Hirotsugu Notsuda, Hirokazu Ogino, Rika Ando, Yoshihisa Tomioka, Takashi Suzuki, Yoshinori Okada, Yasuhiko Nishioka and Michiaki Unno : Diverse and divergent functions of IL-32β and IL-32γ isoforms in the regulation of malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8., Cellular Immunology, Vol.383, 104652, 2023. (Summary) In this study, we sought to elucidate the roles of the interleukin (IL)-32β and IL-32γ in mesothelioma cell growth, and vascular endothelial growth factor (VEGF)-A and C-X-C motif chemokine ligand 8 (CXCL8) expression. IL-32 elicited a growth-promoting effect against one of the six mesotheliomas lines and exerted diverse regulatory functions in VEGF-A and CXCL8 secretion from mesotheliomas stimulated with or without IL-17A. Retroviral-mediated transduction of mesothelioma lines with IL-32γ resulted in enhanced IL-32β expression, which facilitated or suppressed the in vitro growth, and VEGF-A and CXCL8 expression. Overexpressed IL-32β-augmented growth and VEGF-A and CXCL8 production were mainly mediated through the phosphatidylinositol-3 kinase (PI3K) signaling pathway. On the other hand, overexpressed IL-32β-deceased growth was mediated through mitogen-activated protein kinase (MAPK) pathway. NCI-H2373IL-32γ tumors grew faster than NCI-H2373Neo tumors in a xenograft model, which was associated with increased vascularity. These findings indicate that IL-32 are involved in the regulation of growth and angiogenic factor production in mesotheliomas. (Keyword) Humans / Interleukins / Mesothelioma, Malignant / Protein Isoforms / Vascular Endothelial Growth Factor A / Interleukin-8 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.cellimm.2022.104652 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36516653 ● Search Scopus @ Elsevier (PMID): 36516653 ● Search Scopus @ Elsevier (DOI): 10.1016/j.cellimm.2022.104652 (DOI: 10.1016/j.cellimm.2022.104652, PubMed: 36516653)
11.	Makoto Tobiume, Atsushi Mitsuhashi, Atsuro Saijo, Hirokazu Ogino, Tania Afroj, Hirohisa Ogawa, Hisatsugu Goto, Seidai Satou, Akane Abe, Keiko Haji, Ryohiko Ozaki, Hiromitsu Takizawa and Yasuhiko Nishioka : Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer., Oncology Letters, Vol.24, No.5, 417, 2022. (Summary) Fibrocytes, which are bone marrow-derived collagen-producing cells, have been reported to be involved in pathogenesis of pulmonary fibrosis. Our previous study reported that tumor-infiltrating fibrocytes play a role in tumor progression and drug resistance in lung cancer. The present study therefore examined chemotactic factors for fibrocytes in tissues of non-small cell lung cancer (NSCLC) and their prognostic significance. Surgically resected tumor tissues were examined for the expression of chemotactic factors, including C-X-C motif chemokine 12 (CXCL12), CCL2, platelet-derived growth factor (PDGF)-AA and PDGF-BB, as well as tumor-infiltrating fibrocytes by immunostaining. The chemotactic ability of fibrocytes in response to each factor was evaluated using a migration assay by counting the migrated cells microscopically, and expression of receptors for chemotactic factors were analyzed by flow cytometry. The expression of CXCL12, but not CCL2, PDGF-AA, or PDGF-BB, was associated with the number of tumor-infiltrating fibrocytes in lung adenocarcinoma (LUAD), but not lung squamous cell carcinoma (LUSQ). In addition, patients with an increased expression of CXCL12 in LUAD but not LUSQ showed a significantly poorer prognosis compared with those with a decreased expression. However, the expression of CCL2, PDGF-AA and PDGF-BB was not correlated with the prognosis of patients with NSCLC. The number of fibrocytes was associated with a poor prognosis in LUAD. Fibrocytes derived from the peripheral blood of healthy subjects as well as patients with lung cancer expressed higher levels of CXCR4 compared with CCR2, PDGF and receptor-α and receptor-β. Overall, these results suggested that targeting tumor-infiltrating fibrocytes via the CXCL12/CXCR4 axis may be a useful strategy for controlling the progression of NSCLC, particularly LUAD. (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2022.13537 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36245829 ● Search Scopus @ Elsevier (PMID): 36245829 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13537 (DOI: 10.3892/ol.2022.13537, PubMed: 36245829)
12.	Kenji Otsuka, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka : Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease., Thoracic Cancer, Vol.13, No.21, 2978-2984, 2022. (Summary) Second-line chemotherapy among patients with NSCLC complicated by ILD showed a certain effectiveness, but some patients experienced the AE of ILD, which may lead to death. The risk of the AE of ILD must be considered especially for patients with UIP and low percentage VC. (Keyword) Humans / male / Aged / female / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Retrospective Studies / Lung Diseases, Interstitial / Antineoplastic Combined Chemotherapy Protocols (Tokushima University Institutional Repository) ● Metadata: 118615 (Link to Publication Site) ● Publication site (DOI): 10.1111/1759-7714.14645 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36106507 ● Search Scopus @ Elsevier (PMID): 36106507 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.14645 (Tokushima University Institutional Repository: 118615, DOI: 10.1111/1759-7714.14645, PubMed: 36106507)
13.	Eiji Takeuchi, Kensuke Kondo, Yoshio Okano, Michihiro Kunishige, Yoshihiro Kondo, Naoki Kadota, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer., Journal of Cancer Research and Clinical Oncology, Vol.45, 101893, 2022. (Summary) Immune checkpoint inhibitors (ICI) are a promising treatment, but may cause hyperprogressive disease and early death. The present study investigated early mortality factors in ICI monotherapy for lung cancer. (Tokushima University Institutional Repository) ● Metadata: 118880 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00432-022-04215-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35871700 ● Search Scopus @ Elsevier (PMID): 35871700 ● Search Scopus @ Elsevier (DOI): 10.1007/s00432-022-04215-7 (Tokushima University Institutional Repository: 118880, DOI: 10.1007/s00432-022-04215-7, PubMed: 35871700)
14.	Takumi Sakurada, Hiroshi Nokihara, Tadashi Koga, Yoshito Zamami, Mitsuhiro Goda, Kenta Yagi, Hirofumi Hamano, Fuka Aizawa, Hirokazu Ogino, Seidai Satou, Yasushi Kirino, Hisatsugu Goto, Yasuhiko Nishioka and Keisuke Ishizawa : Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study., The Oncologist, Vol.27, No.7, e554-e560, 2022. (Summary) Prophylactic administration of low-dose dexamethasone for 5 days from the day after pemetrexed administration resulted in a milder incidence and severity of rash. These findings may provide a standard preventative strategy for pemetrexed-induced rashes. (Trial identifier: UMIN000025666). (Keyword) Adrenal Cortex Hormones / Carcinoma, Non-Small-Cell Lung / Cisplatin / Dexamethasone / Exanthema / Humans / Lung Neoplasms / Mesothelioma, Malignant / Pemetrexed (Tokushima University Institutional Repository) ● Metadata: 117391 (Link to Publication Site) ● Publication site (DOI): 10.1093/oncolo/oyab077 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35325241 ● Search Scopus @ Elsevier (PMID): 35325241 ● Search Scopus @ Elsevier (DOI): 10.1093/oncolo/oyab077 (Tokushima University Institutional Repository: 117391, DOI: 10.1093/oncolo/oyab077, PubMed: 35325241)
15.	Hiroshi Nokihara, Hirokazu Ogino, Atsushi Mitsuhashi, Kensuke Kondo, Ei Ogawa, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Kenji Otsuka and Yasuhiko Nishioka : Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion., BMC Cancer, Vol.22, No.1, 2022. (Summary) These data suggest the efficacy of osimertinib may differ between EGFR T790M-positive and -negative NSCLC patients with PE. (Keyword) Acrylamides / Aniline Compounds / Carcinoma, Non-Small-Cell Lung / ErbB Receptors / Humans / Lung Neoplasms / Mutation / Pleural Effusion / Protein Kinase Inhibitors / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 117282 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12885-022-09701-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35650550 ● Search Scopus @ Elsevier (PMID): 35650550 ● Search Scopus @ Elsevier (DOI): 10.1186/s12885-022-09701-2 (Tokushima University Institutional Repository: 117282, DOI: 10.1186/s12885-022-09701-2, PubMed: 35650550)
16.	Jun Kako, Masamitsu Kobayashi, Kohei Kajiwara, Yasutaka Kimura, Yasufumi Oosono, Mizuki Takegata, Kimiko Nakano, Yoshinobu Matsuda, Naomi Nakamura, Natsuki Kawashima, Yuta Hirano, Misako Kitae, Kakuhiro Yamaguchi, Hiroshi Iwamoto, Noboru Hattori, Hiroyuki Sawatari, Satoshi Shiono, Hirokazu Ogino, Yasuhiko Nishioka, Koji Amano and Janelle Yorke : Validity and Reliability of the Japanese Version of the Dyspnea-12 Questionnaire in Patients With Lung Cancer., Journal of Pain and Symptom Management, Vol.64, No.2, e83-e89, 2022. (Summary) The Japanese version of the Dyspnea-12 questionnaire is a useful and reliable tool to assess the multi-dimensional aspects of dyspnea in patients with lung cancer. (Keyword) Dyspnea / Humans / Japan / Lung Neoplasms / Psychometrics / Pulmonary Disease, Chronic Obstructive / Reproducibility of Results / Surveys and Questionnaires (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jpainsymman.2022.04.171 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35452793 ● Search Scopus @ Elsevier (PMID): 35452793 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jpainsymman.2022.04.171 (DOI: 10.1016/j.jpainsymman.2022.04.171, PubMed: 35452793)
17.	Hirokazu Ogino, W Jennie Taylor, Takahide Nejo, David Gibson, B Payal Watchmaker, Kaori Okada, Atsuro Saijo, R Meghan Tedesco, Anny Shai, M Cynthia Wong, E Jane Rabbitt, R Michael Olin, L Christopher Moertel, Yasuhiko Nishioka, M Andres Salazar, M Annette Molinaro, J Joanna Phillips, A Nicholas Butowski, L Jennifer Clarke, Ann Bush Nancy Oberheim, L Shawn Hervey-Jumper, Philip Theodosopoulos, M Susan Chang, S Mitchel Berger and Hideho Okada : Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas., The Journal of Clinical Investigation, Vol.132, No.3, 2022. (Summary) BACKGROUNDLong-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk of recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system of patients with LGGs and the slow tumor growth rate, vaccines are an attractive treatment strategy.METHODSWe conducted a pilot study to evaluate the safety and immunological effects of vaccination with GBM6-AD, lysate of an allogeneic glioblastoma stem cell line, with poly-ICLC in patients with LGGs. Patients were randomized to receive the vaccines before surgery (arm 1) or not (arm 2) and all patients received adjuvant vaccines. Coprimary outcomes were to evaluate safety and immune response in the tumor.RESULTSA total of 17 eligible patients were enrolled - 9 in arm 1 and 8 in arm 2. This regimen was well tolerated with no regimen-limiting toxicity. Neoadjuvant vaccination induced upregulation of type-1 cytokines and chemokines and increased activated CD8+ T cells in peripheral blood. Single-cell RNA/T cell receptor sequencing detected CD8+ T cell clones that expanded with effector phenotype and migrated into the tumor microenvironment (TME) in response to neoadjuvant vaccination. Mass cytometric analyses detected increased tissue resident-like CD8+ T cells with effector memory phenotype in the TME after the neoadjuvant vaccination.CONCLUSIONThe regimen induced effector CD8+ T cell response in peripheral blood and enabled vaccine-reactive CD8+ T cells to migrate into the TME. Further refinements of the regimen may have to be integrated into future strategies.TRIAL REGISTRATIONClinicalTrials.gov NCT02549833.FUNDINGNIH (1R35NS105068, 1R21CA233856), Dabbiere Foundation, Parker Institute for Cancer Immunotherapy, and Daiichi Sankyo Foundation of Life Science. (Keyword) adult / Aged / CD8-Positive T-Lymphocytes / Cancer Vaccines / Carboxymethylcellulose Sodium / female / Glioma / Humans / male / Middle Aged / Neoadjuvant Therapy / Poly I-C / Polylysine / Tumor Microenvironment / Vaccination (Tokushima University Institutional Repository) ● Metadata: 117337 (Link to Publication Site) ● Publication site (DOI): 10.1172/JCI151239 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34882581 ● Search Scopus @ Elsevier (PMID): 34882581 ● Search Scopus @ Elsevier (DOI): 10.1172/JCI151239 (Tokushima University Institutional Repository: 117337, DOI: 10.1172/JCI151239, PubMed: 34882581)
18.	Yutaka Morita, Atsuro Saijo, Hiroshi Nokihara, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Yoshimi Bando and Yasuhiko Nishioka : Radiation therapy induces an abscopal effect and upregulates programmed death-ligand 1 expression in a patient with non-small cell lung cancer., Thoracic Cancer, Vol.13, No.7, 1079-1082, 2022. (Summary) T cells, occasionally resulting in a systemic immune response to the tumor outside of the treatment field. The phenomenon of tumor regression at the site distant from irradiated fields is known as the abscopal effect. Several case reports have indicated a potential role of RT in overcoming primary and acquired resistance against immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) and melanoma patients. We herein report an NSCLC patient who developed acquired resistance to an RT-induced abscopal effect and subsequently experienced reactivation of the systemic antitumor immune response by pembrolizumab, an antiprogrammed death 1 antibody. In this case, RT not only induced an abscopal effect but also upregulated the programmed death-ligand 1 expression outside of the irradiated field when the patient developed resistance to the abscopal effect. This case can facilitate our understanding of the mechanism underlying the RT-induced systemic immune response against cancer cells and adaptive resistance mechanism of cancer cells from immune surveillance. These findings highlight the promising results of current clinical trials combining RT and immune checkpoint inhibitors. Ongoing clinical trials will further establish evidence supporting combination therapy with RT and immune checkpoint inhibitors. (Keyword) B7-H1 Antigen / CD8-Positive T-Lymphocytes / Carcinoma, Non-Small-Cell Lung / Humans / Lung Neoplasms (Tokushima University Institutional Repository) ● Metadata: 117392 (Link to Publication Site) ● Publication site (DOI): 10.1111/1759-7714.14330 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35064748 ● Search Scopus @ Elsevier (PMID): 35064748 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.14330 (Tokushima University Institutional Repository: 117392, DOI: 10.1111/1759-7714.14330, PubMed: 35064748)
19.	Masahiro Sako, Hiroshi Nokihara, Kensuke Kondo, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Akane Abe, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka, Hisanori Uehara and Yasuhiko Nishioka : A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab., Thoracic Cancer, Vol.13, No.1, 129-132, 2021. (Summary) Pulmonary pleomorphic carcinoma is often refractory to chemotherapy and follows an aggressive clinical course. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced lung cancer, and a few cases with pleomorphic carcinoma have been reported to show tumor shrinkage after therapy with ICIs. When treating patients with ICIs, patient selection is essential, and monitoring and management of immune-related adverse events, including pneumonitis, are needed. We herein report a case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia treated with pembrolizumab, antiprogrammed cell death 1 antibody. Our report highlights important considerations necessary when treating advanced pleomorphic carcinoma patients complicated with interstitial pneumonia. We also review the literature regarding the use of ICIs in such patients. (Keyword) Aged / Antibodies, Monoclonal, Humanized / Carcinoma, Non-Small-Cell Lung / Humans / Immune Checkpoint Inhibitors / Lung Diseases, Interstitial / Lung Neoplasms / male (Tokushima University Institutional Repository) ● Metadata: 117393 (Link to Publication Site) ● Publication site (DOI): 10.1111/1759-7714.14243 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34859591 ● Search Scopus @ Elsevier (PMID): 34859591 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.14243 (Tokushima University Institutional Repository: 117393, DOI: 10.1111/1759-7714.14243, PubMed: 34859591)
20.	Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka : Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma., BMC Pulmonary Medicine, Vol.21, No.1, 2021. (Summary) This is the first study to report the correlation between irAEs and therapeutic effects in patients with MPM. Because the presence of irAEs may be associated with a favorable clinical outcome, early detection and appropriate management of irAEs will increase the therapeutic benefits to patients. (Keyword) Aged / Aged, 80 and over / Antineoplastic Agents, Immunological / female / Humans / Immune System Diseases / Male / Mesothelioma, Malignant / Middle Aged / Nivolumab / Retrospective Studies / Survival Analysis / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 117283 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12890-021-01746-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34781910 ● Search Scopus @ Elsevier (PMID): 34781910 ● Search Scopus @ Elsevier (DOI): 10.1186/s12890-021-01746-6 (Tokushima University Institutional Repository: 117283, DOI: 10.1186/s12890-021-01746-6, PubMed: 34781910)
21.	Atsushi Mitsuhashi, Kensuke Kondoh, Kazuki Horikawa, Kazuya Koyama, Thi Na Nguyen, Tania Afroj, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : Programmed death (PD)-1/PD-ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker., Cancer Science, Vol.112, No.12, 4853-4866, 2021. (Summary) Immune checkpoint inhibitor (ICI) programmed death (PD)-1/PD-ligand 1 (PD-L1) blockade has been approved for various cancers. However, the underlying antitumor mechanisms mediated by ICIs and the predictive biomarkers remain unclear. We report the effects of anti-PD-L1/PD-1 Ab in tumor angiogenesis. In syngeneic mouse models, anti-PD-L1 Ab inhibited tumor angiogenesis and induces net-like hypoxia only in ICI-sensitive cell lines. In tumor tissue and serum of ICI-sensitive cell line-bearing mice, interferon-γ (IFN-γ) inducible angiostatic chemokines CXCL10/11 were upregulated by PD-L1 blockade. In vitro, CXCL10/11 gene upregulation by IFN-γ stimulation in tumor cell lines correlated with the sensitivity of PD-L1 blockade. The CXCL10/11 receptor CXCR3-neutralizing Ab or CXCL11 silencing in tumor cells inhibited the antiangiogenic effect of PD-L1 blockade in vivo. In pretreatment serum of lung carcinoma patients receiving anti-PD-1 Ab, the concentration of CXCL10/11 significantly correlated with the clinical outcome. Our results indicate the antiangiogenic function of PD-1/PD-L1 blockade and identify tumor-derived CXCL10/11 as a potential circulating biomarker of therapeutic sensitivity. (Keyword) Animals / B7-H1 Antigen / Biomarkers, Tumor / Carcinoma, Non-Small-Cell Lung / Cell Line, Tumor / Chemokine CXCL10 / Chemokine CXCL11 / HEK293 Cells / Humans / Immune Checkpoint Inhibitors / Interferon-gamma / Lung Neoplasms / male / Mice, Inbred BALB C / Mice, Inbred C57BL / Mice, Inbred CBA / Mice, Nude / Neoplasms, Experimental / Neovascularization, Pathologic / Programmed Cell Death 1 Receptor / RNA Interference (Tokushima University Institutional Repository) ● Metadata: 117305 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.15161 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34628702 ● Search Scopus @ Elsevier (PMID): 34628702 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15161 (Tokushima University Institutional Repository: 117305, DOI: 10.1111/cas.15161, PubMed: 34628702)
22.	Hirokazu Ogino, Makoto Tobiume, Kozo Kagawa, Hiroshi Kawano, Satoshi Sakaguchi, Atsuro Saijo, Daisuke Matsumoto, Hiromitsu Takizawa, Yuriko Morikawa, Yoshimi Bando, Hisatsugu Goto, Hiroshi Nokihara and Yasuhiko Nishioka : A Case of Radiation-associated Angiosarcoma Presenting as Massive Pleural Effusion., Internal Medicine, Vol.61, No.9, 1393-1397, 2021. (Summary) A 67-year-old man was admitted to our hospital for massive pleural effusion. He had a history of mandibular gingival carcinoma treated with radiation therapy (RT). Based on the cytology findings of pleural effusion and a thoracoscopic pleural biopsy, we finally diagnosed him with radiation-associated angiosarcoma. Retrospective cell-block immunocytochemistry with pleural effusion also showed potential utility for the diagnosis. This case highlights the importance of considering the possibility of radiation-associated secondary cancer in patients with pleural effusion who have a history of RT. (Keyword) Aged / Biopsy / Hemangiosarcoma / Humans / male / Pleural Effusion / Retrospective Studies / Thoracoscopy (Tokushima University Institutional Repository) ● Metadata: 118013 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.8195-21 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34645765 ● Search Scopus @ Elsevier (PMID): 34645765 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.8195-21 (Tokushima University Institutional Repository: 118013, DOI: 10.2169/internalmedicine.8195-21, PubMed: 34645765)
23.	Tania Afroj, Atsushi Mitsuhashi, Hirokazu Ogino, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Makoto Tobiume, Thi Na Nguyen, Hisatsugu Goto, Kazuya Koyama, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara and Yasuhiko Nishioka : Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes., The Journal of Immunology, Vol.206, No.6, 1204-1214, 2021. (Summary) T cells when the activity is further enhanced by PD-L1/PD-1 blockade. (Tokushima University Institutional Repository) ● Metadata: 115981 (Link to Publication Site) ● Publication site (DOI): 10.4049/jimmunol.2000909 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33504617 ● Search Scopus @ Elsevier (PMID): 33504617 ● Search Scopus @ Elsevier (DOI): 10.4049/jimmunol.2000909 (Tokushima University Institutional Repository: 115981, DOI: 10.4049/jimmunol.2000909, PubMed: 33504617)
24.	Kenji Otsuka, Atsushi Mitsuhashi, Hisatsugu Goto, Masaki Hanibuchi, Kazuya Koyama, Hirohisa Ogawa, Hirokazu Ogino, Atsuro Saijo, Hiroyuki Kozai, Hiroto Yoneda, Makoto Tobiume, Masatoshi Kishuku, Keisuke Ishizawa and Yasuhiko Nishioka : Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells., Lung Cancer, Vol.146, 86-96, 2020. (Summary) T cells in tumors, the number of Foxp3 (Keyword) Animals / Cell Line, Tumor / Lung Neoplasms / Mesothelioma / Mice / Myeloid-Derived Suppressor Cells / Pemetrexed (Tokushima University Institutional Repository) ● Metadata: 115324 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.lungcan.2020.05.023 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32526602 ● Search Scopus @ Elsevier (PMID): 32526602 ● Search Scopus @ Elsevier (DOI): 10.1016/j.lungcan.2020.05.023 (Tokushima University Institutional Repository: 115324, DOI: 10.1016/j.lungcan.2020.05.023, PubMed: 32526602)
25.	Asami Fukuya, Hirokazu Ogino, 坪井未希, Mayo Kondou, Kozo Kagawa, Masaki Hanibuchi, 山﨑博輝, Ryosuke Miyamoto, Yuko Toyoda and Yasuhiko Nishioka : エタンブトールによる脱髄性末梢神経障害により急速進行性の歩行障害を呈した結核性胸膜炎の1例, 日本結核・非結核性抗酸菌症学会, Vol.95, No.2, 73-77, 2020.
26.	Masaki Hanibuchi, Akira Kanoh, Takuya Kuramoto, Tatsuro Saito, Makoto Tobiume, Atsuro Saijo, Hiroyuki Kozai, Mayo Kondou, Shun Morizumi, Hiroto Yoneda, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Kenji Otsuka, Yuko Toyoda, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : Development, validation, and comparison of gene analysis methods for detecting mutation from non-small cell lung cancer patients-derived circulating free DNA., Oncotarget, Vol.10, No.38, 3654-3666, 2019. (Tokushima University Institutional Repository) ● Metadata: 115668 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.26951 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31217900 ● Search Scopus @ Elsevier (PMID): 31217900 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.26951 (Tokushima University Institutional Repository: 115668, DOI: 10.18632/oncotarget.26951, PubMed: 31217900)
27.	Atsuro Saijo, Masaki Hanibuchi, Hirokazu Ogino, Kenji Otsuka, Hisatsugu Goto, Hiroshi Nokihara and Yasuhiko Nishioka : Paclitaxel for relapsed small-cell lung cancer patients with idiopathic interstitial pneumonias., Molecular and Clinical Oncology, Vol.10, No.5, 541-546, 2019. (Summary) Although first-line chemotherapy is highly sensitive against small-cell lung cancer (SCLC), most patients subsequently experience disease progression. Topotecan is the standard therapy for sensitive-relapsed SCLC patients, and subgroup analysis of a randomized phase III trial suggests that amrubicin is effective for refractory-relapsed SCLC. However, because of the lack of the evidence based on clinical trials, the effectiveness of systemic chemotherapy for relapsed SCLC patients with idiopathic interstitial pneumonias (IIPs) is unclear. In the presentstudy, 17 relapsed SCLC patients with IIPs who received a paclitaxel (PTX)-containing regimen as a second-line chemotherapy were retrospectively reviewed. The overall response rate and the disease control rate of the PTX-containing regimens were 29.4 and 47.1%, respectively. The median progression-free survival and the overall survival of the regimens were 2.7 months [95% confidence interval (CI), 1.6-3.6 months] and 3.6 months (95% CI, 2.3-14.0 months), respectively. Grade 3-4 neutropenia and febrile neutropenia occurred in 12 (70.6%) and 2 (11.8%) patients, respectively. During the treatment period, acute exacerbation (AE) of IIPs was observed in five patients (29.4%). Treatment-associated fatality was observed in 1 patient with febrile neutropenia and in 1 patient with AE of IIPs. PTX had promising anti-tumor activity against refractory-relapsed SCLC with IIPs. However, the survival benefit of the treatment was limited because of the high incidence of AE of IIPs and treatment-related death. (Link to Publication Site) ● Publication site (DOI): 10.3892/mco.2019.1828 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30967948 ● Search Scopus @ Elsevier (PMID): 30967948 ● Search Scopus @ Elsevier (DOI): 10.3892/mco.2019.1828 (DOI: 10.3892/mco.2019.1828, PubMed: 30967948)
28.	Taichi Murakami, Masanori Tamaki, Seiji Kishi, Kojiro Nagai, Hideharu Abe, Yoshimi Bando, Yuko Toyoda, Hirokazu Ogino, Yasuhiko Nishioka, Sayo Ueda, Toshio Doi and Motokazu Matsuura : Systemic Sarcoidosis Presenting with Renal Involvement Caused by Various Sarcoidosis-associated Pathophysiological Conditions, Internal Medicine, Vol.58, No.5, 679-684, 2019. (Summary) A 61-year-old man was diagnosed with sarcoidosis involving the lungs, eyes, parotid gland and extrathoracic lymph nodes complicated by chronic kidney injury and hypercalcemia. Kidney biopsy showed non-specific interstitial nephritis and nephrosclerosis. However, immunohistochemical staining of cell surface markers revealed a multinucleated giant macrophage surrounded by T-cells, suggesting granulomatous interstitial nephritis. Corticosteroid improved the kidney function, and reduced the serum levels of calcium and angiotensin-converting enzyme. Sarcoid nephropathy may be caused by the combination of several sarcoidosis-associated pathophysiological conditions and a comprehensive kidney examination should be performed to assess the type of injury when determining a treatment strategy. (Keyword) Biomarkers / Biopsy / calcium / Glucocorticoids / Humans / Hypercalcemia / Kidney / male / Middle Aged / Nephritis, Interstitial / Nephrosclerosis / Peptidyl-Dipeptidase A / Radionuclide Imaging / Sarcoidosis (Tokushima University Institutional Repository) ● Metadata: 114405 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.1558-18 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30449791 ● Summary page in Scopus @ Elsevier: 2-s2.0-85062415769 (Tokushima University Institutional Repository: 114405, DOI: 10.2169/internalmedicine.1558-18, PubMed: 30449791, Elsevier: Scopus)
29.	Hirokazu Ogino, Masaki Hanibuchi, Satoshi Sakaguchi, Yuko Toyoda, Toshifumi Tezuka, Hiroshi Kawano, Soji Kakiuchi, Kenji Otsuka, Atsuro Saijo, Masahiko Azuma, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : The clinical features of older patients with lung cancer in comparison with their younger counterparts., Respiratory Investigation, Vol.57, No.1, 40-48, 2019. (Summary) We should positively consider standard treatments for older patients. However, not only their shorter life expectancy but also their poor PS and multiple comorbidities that sometimes render patients unable to receive standard treatments and several chemotherapy regimens, make their prognosis poor. The standard treatments for older patients, especially in locally advanced stages, require modification. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.resinv.2018.10.003 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30448243 ● Search Scopus @ Elsevier (PMID): 30448243 ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2018.10.003 (DOI: 10.1016/j.resinv.2018.10.003, PubMed: 30448243)
30.	Mayo Kondo, Hirokazu Ogino, Hirohisa Ogawa, Tania Afroj, Yuko Toyoda, Satoshi Sakaguchi, Miki Tsuboi, Yoshimi Bando, Hisatsugu Goto, Koichi Tsuneyama and Yasuhiko Nishioka : A case of pulmonary pleomorphic carcinoma with malignant phenotypes induced by ZEB1-associated epithelial-mesenchymal transition., Respiratory Medicine Case Reports, Vol.25, 119-121, 2018. (Summary) A 60-year-old man was admitted to our hospital with non-small cell lung cancer (NSCLC). Imaging and pathological studies revealed NSCLC, not otherwise specified (NOS), at clinical stage T3N1M0 stage IIIA. We started radiotherapy alone because of obstructive pneumonia and end-stage renal disease, but the tumors progressed rapidly and resulted in death due to air obstruction by pharyngeal metastasis. The cancer was diagnosed as pleomorphic carcinoma in an autopsy. Viable lung tumor cells, which were resistant to radiotherapy, and the pharyngeal metastasis had mesenchymal phenotypes and expressed ZEB1 but not SNAI1. These observations indicated that ZEB1-associated epithelial-mesenchymal transition has malignant features including resistance to radiotherapy and aggressive metastatic potential. ZEB1-associated EMT may be an important mechanism to understand the pathophysiology of pleomorphic carcinoma. (Tokushima University Institutional Repository) ● Metadata: 115710 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.rmcr.2018.07.008 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30112272 ● Search Scopus @ Elsevier (PMID): 30112272 ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2018.07.008 (Tokushima University Institutional Repository: 115710, DOI: 10.1016/j.rmcr.2018.07.008, PubMed: 30112272)
31.	Hirokazu Ogino, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Toshifumi Tezuka, Yuko Toyoda, Makoto Tobiume, Kenji Otsuka, Satoshi Sakaguchi, Hisatsugu Goto, Kokichi Arisawa and Yasuhiko Nishioka : Analysis of the prognostic factors of extensive disease small-cell lung cancer patients in Tokushima University Hospital, The Journal of Medical Investigation : JMI, Vol.63, No.3 4, 286-293, 2016. (Summary) Small-cell lung cancer (SCLC) presents aggressive clinical behavior, and its prognosis is still poor. Previously, performance status (PS), or the existence of brain, bone, or liver metastasis were reported to be unfavorable prognostic factors. Given the recent progress of treatment modalities such as radiotherapy techniques and bone modifying agents, the prognostic factors might be different from previous findings. Therefore, we analyzed the prognostic factors of extensive disease SCLC (ED-SCLC) in recent years. ED-SCLC patients treated in Tokushima University Hospital between 2010 and 2016 were analyzed. Log-rank test and the Cox proportional hazards regression model was used in univariate and multivariate analysis, respectively. Totally, 79 patients were analyzed. In the univariate analysis, age, PS, interstitial pneumonia (IP), liver metastasis, pleural dissemination, neutrophil counts, hypoalbuminemia, hypercalcemia and several liver and biliary enzymes were identified as poor prognostic factors. In the multivariate analysis, age, PS, IP, and liver and biliary enzymes were identified. Moreover, the PS in patients with liver metastasis was significantly worsened. In this study, we newly demonstrated that IP was a significant poor prognostic factor of ED-SCLC. Although liver metastasis was not extracted in multivariate analysis, it may have an impact on the prognosis of ED-SCLC. J. Med. Invest. 63: 286-293, August, 2016. (Tokushima University Institutional Repository) ● Metadata: 111196 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.63.286 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27644574 ● Summary page in Scopus @ Elsevier: 2-s2.0-84987918312 (Tokushima University Institutional Repository: 111196, DOI: 10.2152/jmi.63.286, PubMed: 27644574, Elsevier: Scopus)
32.	山子泰斗, Masaki Hanibuchi, Hirokazu Ogino, 村上永尚, Ryuji Kaji and Yasuhiko Nishioka : A Case of Small Cell Lung Cancer with Diverse Neurological Symptoms due to Paraneoplastic Neurological Syndrome, Japanese Journal of Lung Cancer, Vol.56, No.3, 199-204, 2016. (Summary) <b><i>Background. </i></b>Paraneoplastic neurological syndrome is a neurological disorder associated with various malignancies and is considered to be caused by autoimmune mechanisms, but not by symptoms due to tumor progression itself. Small cell lung cancer is the most common type of malignancy accompanied with paraneoplastic neurological syndrome. <b><i>Case. </i></b>A 77-year-old male was referred to our hospital for further examination of general fatigue, gait disturbance and dysuria. On admission, diverse neurological symptoms, such as dysarthria, dysphagia, motor and sensory disturbance in lower extremities and autonomic dysregulation, were observed. Further examination yielded the diagnosis of Lambert-Eaton myasthenic syndrome with positive results for anti-amphiphysin and anti-ganglioside antibodies. Swelling of the mediastinal lymph nodes and elevated ProGRP were detected, and a definitive diagnosis of small cell lung cancer (cTXN2M1b: Stage IV) was made. As the administration of intravenous immunoglobulin failed to ameliorate his neurological symptoms and general condition (PS 4), we determined that there were no indications for chemotherapy. He was subsequently transferred to a palliative care hospital and died nearly one year after the development of his initial symptoms. <b><i>Conclusion. </i></b>We experienced a case of small cell lung cancer with diverse neurological symptoms due to the presence of paraneoplastic neurological syndrome. (Keyword) Paraneoplastic neurological syndrome / Small cell lung cancer / Lambert-Eaton myasthenic syndrome / Anti-amphiphysin antibody / Anti-ganglioside antibody (Tokushima University Institutional Repository) ● Metadata: 117547 (Link to Publication Site) ● Publication site (DOI): 10.2482/haigan.56.199 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204681086464 ● Search Scopus @ Elsevier (DOI): 10.2482/haigan.56.199 (Tokushima University Institutional Repository: 117547, DOI: 10.2482/haigan.56.199, CiNii: 1390001204681086464)
33.	Hirokazu Ogino, Masaki Hanibuchi, Hiromitsu Takizawa, Shoji Sakiyama, Sumitomo Hiroyuki, Seiji Iwamoto, Hitoshi Ikushima, Nakajima Kohei, Shinji Nagahiro, Yamago Taito, Yuko Toyoda, Yoshimi Bando and Yasuhiko Nishioka : Primary Pulmonary Synovial Sarcoma Showing a Prolonged Survival with Multimodality Therapy, Internal Medicine, Vol.55, No.4, 381-387, 2016. (Summary) A 54-year-old man was referred to our hospital due to a mass shadow noted on a chest X-ray. Thoracoscopic lobectomy yielded a diagnosis of primary pulmonary synovial sarcoma according to the histology and SYT-SSX1 gene analyses. Five months after the thoracic surgery, he developed brain metastasis; therefore, we performed resection of the brain metastatic focus followed by radiotherapy. As a local recurrence in the thoracic cavity concurrently emerged, systemic chemotherapy was also administered. These observations indicated that a multidisciplinary approach may be useful against primary pulmonary synovial sarcoma, although there is presently no established therapeutic strategy due to its rarity and highly aggressive nature. (Tokushima University Institutional Repository) ● Metadata: 114387 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.55.5169 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26875964 ● Search Scopus @ Elsevier (PMID): 26875964 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.55.5169 (Tokushima University Institutional Repository: 114387, DOI: 10.2169/internalmedicine.55.5169, PubMed: 26875964)
34.	Mitsuhashi Atsushi, Hisatsugu Goto, Atsuro Saijo, Trung The Van, Yoshinori Aono, Hirokazu Ogino, Kuramoto Takuya, Tabata Sho, Hisanori Uehara, Keisuke Izumi, Mitsuteru Yoshida, Kobayashi Hiroaki, Takahashi Hidefusa, Gotoh Masashi, Kakiuchi Soji, Masaki Hanibuchi, Seiji Yano, Yokomise Hiroyasu, Shoji Sakiyama and Yasuhiko Nishioka : Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab, Nature Communications, Vol.6, 8792, 2015. (Summary) Bevacizumab exerts anti-angiogenic effects in cancer patients by inhibiting vascular endothelial growth factor (VEGF). However, its use is still limited due to the development of resistance to the treatment. Such resistance can be regulated by various factors, although the underlying mechanisms remain incompletely understood. Here we show that bone marrow-derived fibrocyte-like cells, defined as alpha-1 type I collagen-positive and CXCR4-positive cells, contribute to the acquired resistance to bevacizumab. In mouse models of malignant pleural mesothelioma and lung cancer, fibrocyte-like cells mediate the resistance to bevacizumab as the main producer of fibroblast growth factor 2. In clinical specimens of lung cancer, the number of fibrocyte-like cells is significantly increased in bevacizumab-treated tumours, and correlates with the number of treatment cycles, as well as CD31-positive vessels. Our results identify fibrocyte-like cells as a promising cell biomarker and a potential therapeutic target to overcome resistance to anti-VEGF therapy. (Tokushima University Institutional Repository) ● Metadata: 115640 (Link to Publication Site) ● Publication site (DOI): 10.1038/ncomms9792 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26635184 ● Summary page in Scopus @ Elsevier: 2-s2.0-84949310071 (Tokushima University Institutional Repository: 115640, DOI: 10.1038/ncomms9792, PubMed: 26635184, Elsevier: Scopus)

Review, Commentary:

1.	Hirokazu Ogino and Yasuhiko Nishioka : 間質性肺炎合併非小細胞肺癌に対する薬物療法について, BIO Clinica, Vol.36, No.11, 41-47, Oct. 2021.
2.	Hirokazu Ogino, Hisatsugu Goto and Yasuhiko Nishioka : 咳嗽の原因として見逃してはならない腫瘍, 呼吸器ジャーナル, Vol.66, No.3, 458-465, Aug. 2018.
3.	Hirokazu Ogino and Yasuhiko Nishioka : がん転移の臨床研究の歴史と展望, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.75, No.8, 15-20, Nov. 2017.

Proceeding of International Conference:

1.	Atsushi Mitsuhashi, Kazuya Koyama, Afroj Tania, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, Sugimoto Masamichi, Kondoh Osamu, Hiroshi Nokihara and Yasuhiko Nishioka : The identification and analysis of fibrocyte regulating the tumor immune microenvironment, The 9th Joint Meeting 2023 (Tokushima Univ., Gifu Univ., SNU, and IBS-KAIST)., Daejeon, Oct. 2023.
2.	Yabuki Yohei, Kenji Otsuka, Hirokazu Ogino, Takeuchi Eiji, Haku Takashi, Takanori Kanematsu, Nishimura Naoki, Yuko Toyoda, Masaki Hanibuchi, Atsushi Mitsuhashi, Tsukazaki Yuki, Ryohiko Ozaki, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka : A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer, APSR 2022, Seoul, Nov. 2022.
3.	Ryohiko Ozaki, Hiroshi Nokihara, Yabuki Youhei, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino and Yasuhiko Nishioka : The examination of the second-line chemotherapy in SCLC patients with interstitial lung disease, ERS International Congress 2022, Barcelona, Sep. 2022.
4.	Nguyen Na Thi, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Afroj Tania, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka : S-1 reduces myeloid-derived suppressor cells in murine mesothelioma model and enhances the anti-tumor activity of anti-PD-1 antibody, APSR 2021, Kyoto and online, Nov. 2021.
5.	Ryohiko Ozaki, Hiroshi Nokihara, Atsushi Mitsuhashi, Kondou Kensuke, YABUKI Yohhei, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka : The clinical efficacy and safety of the second-line chemotherapy in extensive-disease small cell lung cancer patients with interstitial lung disease, APSR 2021, Kyoto and online, Nov. 2021.
6.	Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, YABUKI Yohhei, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka : Association of immune-related adverse events with therapeutic response to Nivolumab in patients with malignant pleural mesothelioma, APSR 2021, Kyoto and online, Nov. 2021.
7.	Hirokazu Ogino, Afroj Tania, Atsushi Mitsuhashi, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Nguyen Thi Na, Kozo Kagawa, Sugimoto Masamichi, Kondoh Osamu, Hiroshi Nokihara and Yasuhiko Nishioka : Antigen-presenting capacity of fibrocytes and its regulation by anti-PD-1/PD-L1 antibodies, APSR 2021, Kyoto and online, Nov. 2021.
8.	Hisatsugu Goto, Yamago Taito, Atsuro Saijo, Hirokazu Ogino, Tobiume Makoto, Otsuka Kenji, Hiroyuki Kozai, Yoneda Hiroto, Hiroshi Nokihara and Yasuhiko Nishioka : Involvement of insulin-like growth factor in RANKL-targeted therapy in mouse model of lung cancer bone metastasis., ATS 2018 International Conference, San Diego, May 2018.
9.	Hirokazu Ogino, Hisatsugu Goto, Okano Yoshio, Machida Hisanori, Hatakeyama Nobuo, Ogushi Fumitaka, Haku Takashi, Takanori Kanematsu, Tomoyuki Urata, Souji Kakiuchi, Masaki Hanibuchi, Saburo Sone and Yasuhiko Nishioka : Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer., ERS International Congress 2017, Milan, Italy, Sep. 2017.
10.	Atsuro Saijo, Hisatsugu Goto, Mayuri Nakano, Mitsuhashi Atsushi, Hirokazu Ogino, Makoto Tobiume, Kenji Ohtsuka, Hiroto Yoneda, Masaki Hanibuchi and Yasuhiko Nishioka : Bone Marrow-Derived Fibrocytes Promote Stem Cell-Like Properties of Lung Cancer Cells., ATS 2017 International Conference, Washington, D.C., May 2017.
11.	Hisatsugu Goto, Mitsuhashi Atsushi, Atsuro Saijo, Hirokazu Ogino, Kenji Ohtsuka, Makoto Tobiume, Hiroto Yoneda, Masaki Hanibuchi and Yasuhiko Nishioka : Fibrocytes as a Possible Cellular Biomarker for Anti-Angiogenic Therapy in Lung Cancer., ATS 2017 International Conference, Washington, D.C., May 2017.
12.	Masaki Hanibuchi, Akira Kanoh, Takuya Kuramoto, Hisatsugu Goto, Atsuro Saijo, Hirokazu Ogino and Yasuhiko Nishioka : Assessment of clinical usability of a cfDNA-based assay detecting EGFR T790M mutation in EGFR-TKI refractory NSCLC patients, The IASLC 17th World Conference on Lung Cancer, Dec. 2016.
13.	Hirokazu Ogino, Hisatsugu Goto, Souji Kakiuchi, Atsuro Saijo, Satoshi Sakaguchi, Makoto Tobiume, Kenji Otsuka, Hiroto Yoneda, Masaki Hanibuchi and Yasuhiko Nishioka : Receptor tyrosine kinase-like orphan receptor 2, ROR2, regulates the proliferation of malignant pleural mesothelioma cells, ATS 2016 International Conference, May 2016.
14.	Atsuro Saijo, Hisatsugu Goto, Atsushi Mitsuhashi, Mayuri Nakano, Hirokazu Ogino, Yoshinori Aono, Satoshi Sakaguchi, Makoto Tobiume, Kenji Otsuka, Masaki Hanibuchi and Yasuhiko Nishioka : Bone-marrow derived fibrocytes maintain stem cell-like properties of lung cancer, ATS 2016 International Conference, May 2016.
15.	Hisatsugu Goto, Mitsuhashi Atsushi, Atsuro Saijo, Yoshinori Aono, Hirokazu Ogino, Hirohisa Ogawa, Souji Kakiuchi, Masaki Hanibuchi and Yasuhiko Nishioka : The role of fibrocytes in the resistance to anti-angiogenic therapy in malignant pleural mesothelioma and lung cancer, International Conference of Cancer Immunotherapy and Macrophages 2015, Tokyo, Jul. 2015.
16.	Hirokazu Ogino, Mitsuhashi Atsushi, Hisatsugu Goto, Atsuro Saijo, Kuramoto Takuya, Tabata Sho, Hisanori Uehara, Souji Kakiuchi, Masaki Hanibuchi and Yasuhiko Nishioka : Characterization of sphere-forming stem-like population of lung cancer cell line in multi-organ metastasis model, ATS 2015 International Conference, Denver, May 2015.

Proceeding of Domestic Conference:

1.	Noriko Bando, Hiroki Bandoh, Keiko Haji, 美馬正人, Asami Fukuya, Nobuhito Naito, Ryohiko Ozaki, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Satoshi Sakaguchi, Masaki Hanibuchi and Yasuhiko Nishioka : 当科における重症喘息に対する生物学的製剤の治療効果の検討, 第268回徳島医学会学術集会, Mar. 2024.
2.	Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yugo Matumura, Seiya Ichihara, Takeshi Imakura, Ryohiko Ozaki, Ei Ogawa, Yutaka Morita, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Masaki Hanibuchi, Yuko Toyoda, Kayoko Hase, Eiji Takeuchi, Takashi Haku and Yasuhiko Nishioka : The impacts of G-CSF on the therapeutic efficacy of chemo-immunotherapy for extensive-stage small cell lung cancer., 2024 the Japanese Society of Medical Oncology Annual Meeting (JSMO2024), Feb. 2024.
3.	Hirokazu Ogino, Nguyen Na Thi, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroshi Nokihara, Masaki Hanibuchi and Yasuhiko Nishioka : Fluoropyrimidine has a potential to be an immunologically optimal partner ofimmunotherapy for thoracic malignancies., 2024 the Japanese Society of Medical Oncology Annual Meeting (JSMO2024), Feb. 2024.
4.	Ryoko Suzue, Hiroki Bandoh, Keiko Haji, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 抗横紋筋抗体陽性の重症irAE筋炎・心筋炎に対して早期の集学的治療が奏効した肺扁平上皮癌の1例, 第69回日本呼吸器学会中国・四国地方会, Dec. 2023.
5.	寺澤翠, Hiroki Bandoh, Keiko Haji, Hiroto Yoneda, Hirokazu Ogino, 岡田直子, Takashi Kawanaka, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : ペプチド受容体放射性核種療法が奏効した左下葉原発進行期非定型カルチノイドの1例, 第69回日本呼吸器学会中国・四国地方会, Dec. 2023.
6.	Kenya Miyamoto, Masaki Hanibuchi, Hiroki Bandoh, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 気管支鏡後の呼吸器感染症のリスク因子および予防的抗菌薬投与の有用性についての検討, 第32回日本呼吸器内視鏡学会中国四国支部会, Dec. 2023.
7.	Hiroshi Kawano, Yu Aoi, Katsuhiro Atagi, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 顕微鏡的多発血管炎の診断時にEBVの再活性化を呈し，リツキシマブにて寛解導入療法を行った1例, 第34回日本リウマチ学会中国・四国支部学術集会, Dec. 2023.
8.	Yu Aoi, Hiroshi Kawano, Katsuhiro Atagi, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 胸膜炎，間質性肺疾患を先行し，発熱性好中球減少症と肺病変の増悪で発症したSLEの1例, 第34回日本リウマチ学会中国・四国支部学術集会, Dec. 2023.
9.	Yuki Tsukazaki, Makoto Tobiume, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino, Masaki Hanibuchi, Hirohisa Ogawa, Hiromitsu Takizawa and Yasuhiko Nishioka : 非小細胞肺癌症例における腫瘍浸潤線維細胞の走化因子と疾患予後との関連性についての解析, 第64回日本肺癌学会学術集会, Nov. 2023.
10.	竹内栄治, Hirokazu Ogino, 近藤健介, 岡野義夫, 松村有悟, 市原聖也, Michihiro Kunishige, 門田直樹, 町田久典, 畠山暢生, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : 好酸球増加は免疫チェックポイント阻害薬治療を受けた非小細胞肺癌患者の効果予測バイオマーカー, 第64回日本肺癌学会学術集会, Nov. 2023.
11.	Hirokazu Ogino, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Masaki Hanibuchi, Hiroshi Nokihara and Yasuhiko Nishioka : フッ化ピリミジンは胸部腫瘍の免疫原性細胞死を誘導し免疫チェックポイント阻害薬の至適併用薬となり得る, 第64回日本肺癌学会学術集会, Nov. 2023.
12.	Ryohiko Ozaki, Hiroshi Nokihara, Yuki Tsukazaki, Yohei Yabuki, Atsushi Mitsuhashi, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka : 進展型小細胞肺癌において2次治療が受けられない患者の臨床的背景の検討, 第64回日本肺癌学会学術集会, Nov. 2023.
13.	Atsushi Mitsuhashi, Hirokazu Ogino, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka : 胸部腫瘍におけるfibrocyteの同定と新規治療標的としての展開, 第64回日本肺癌学会学術集会, Nov. 2023.
14.	Ryohiko Ozaki, 小川瑛, Hiroshi Nokihara, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka : ALK融合遺伝子陽性非小細胞肺癌の効果予測因子に関する検討, 第61回日本癌治療学会学術集会, Oct. 2023.
15.	Yohei Yabuki, Atsushi Mitsuhashi, Hirokazu Ogino, Na Thi Nguyen, Hiroto Yoneda, Ryohiko Ozaki, Yuki Tsukazaki, Masaki Hanibuchi, Hiroshi Nokihara and Yasuhiko Nishioka : HIF1A 阻害による腫瘍細胞由来 CXCL10/11 制御を介した抗 PDL1 抗体への耐性克服, 第82回日本癌学会学術総会, Sep. 2023.
16.	Atsushi Mitsuhashi, Kazuya Koyama, Hirokazu Ogino, 杉本正道, 根東攝, Hiroshi Nokihara and Yasuhiko Nishioka : 腫瘍内 fibrocyte 遊走・分化制御がもたらす腫瘍免疫微小環境への影響, 第82回日本癌学会学術総会, Sep. 2023.
17.	Atsushi Mitsuhashi, Kazuya Koyama, アフローズタニア, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, 杉本正道, 根東攝, Hiroshi Nokihara and Yasuhiko Nishioka : 腫瘍内 fibrocyte の同定と制御による新規がん治療開発への橋渡し研究, 第82回日本癌学会学術総会, Sep. 2023.
18.	中西渓介, Hiroki Bandoh, Keiko Haji, 松村有悟, 稲葉香織, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : Carboplatin+etoposideや放射線治療に不応もnab-paclitaxelが奏効した肺原発大細胞神経内分泌癌の1例, 第128回日本内科学会四国地方会, Jul. 2023.
19.	Atsushi Mitsuhashi, Hirokazu Ogino, Na Thi Nguyen, 矢葺洋平, Hiroto Yoneda, 杉本正道, 根東攝, Hiroshi Nokihara and Yasuhiko Nishioka : 腫瘍内fibrocyteの同定と機能制御による新規複合がん免疫療法の開発, 第32回日本がん転移学会学術集会・総会, Jul. 2023.
20.	Hiroto Yoneda, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroshi Nokihara, Shinji Abe, 金子美華, 加藤幸成 and Yasuhiko Nishioka : 悪性胸膜中皮腫に対する抗ポドプラニン抗体および抗CTLA-4抗体による複合がん免疫療法の検討, 第32回日本がん転移学会学術集会・総会, Jul. 2023.
21.	多田里穂, Hiroki Bandoh, Keiko Haji, 新居香織, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 抗PD-L1抗体投与により腫瘍随伴性小脳変性症が顕在化した小細胞肺癌の1例, 第61回日本肺癌学会中国・四国支部学術集会, Jul. 2023.
22.	遠藤裕美, Hiroki Bandoh, Keiko Haji, 高橋啓輝, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 包括的ゲノムプロファイリングにより診断し得たEGFR Exon19欠失変異陽性肺腺癌の1例, 第61回日本肺癌学会中国・四国支部学術集会, Jul. 2023.
23.	Yuki Tsukazaki, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohhei Yabuki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka : 肺癌における腫瘍浸潤線維細胞の走化因子とその疾患予後に及ぼす影響についての解析, 第27回日本がん分子標的治療学会学術集会, Jun. 2023.
24.	Atsushi Mitsuhashi, Hirokazu Ogino, Na Thi Nguyen, Hiroto Yoneda, Yohhei Yabuki, 杉本正道, 根東攝, Hiroshi Nokihara and Yasuhiko Nishioka : Fibrocyte の分化制御による複合がん免疫療法への展開, 第27回日本がん分子標的治療学会学術集会, Jun. 2023.
25.	Yohhei Yabuki, Atsushi Mitsuhashi, Na Thi Nguyen, Hirokazu Ogino, Hiroto Yoneda, Ryohiko Ozaki and Yasuhiko Nishioka : IFN-g 反応性ケモカイン産生制御機序の解明と新規複合がん免疫療法への応用, 第27回日本がん分子標的治療学会学術集会, Jun. 2023.
26.	Hiroshi Kawano, 小路貴俊, Katsuhiro Atagi, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : リンパ球特異的チロシンキナーゼ阻害薬A-770041は制御性T細胞によるTGF-βs産生抑制を介して肺線維症を改善する, 第67回日本リウマチ学会総会・学術集会, Apr. 2023.
27.	Hirokazu Ogino, Ryohiko Ozaki, Kenji Otsuka, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohhei Yabuki, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka : 間質性肺炎を合併する進行期肺癌に対する二次化学療法の有効性および安全性に関する検討, 第120回日本内科学会講演会, Apr. 2023.
28.	Tsukazaki Yuki, Ogawa Ei, Hiroshi Nokihara, Atsushi Mitsuhashi, Kondo Kensuke, Yabuki Youhei, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka : The prognostic factors for the efficacy of anaplastic lymphoma kinase inhibitors in non-small cell lung cancer, 2023 the Japanese Society of Medical Oncology Annual Meeting, Mar. 2023.
29.	Ryohiko Ozaki, Hiroshi Nokihara, Tukazaki Yuki, Yabuki Yohei, Atsushi Mitsuhashi, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka : Clinical factors of not receiving second-line chemotherapy in ED-SCLC patients, 2023 the Japanese Society of Medical Oncology Annual Meeting, Mar. 2023.
30.	Hirokazu Ogino, Kondo Kensuke, Atsushi Mitsuhashi, Tsukazaki Yuki, Ryohiko Ozaki, Yabuki Yohei, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka : The novel prognostic system for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer, 2023 the Japanese Society of Medical Oncology Annual Meeting, Mar. 2023.
31.	松村有悟, Keiko Haji, 鈴江涼子, Hiroto Yoneda, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hirohisa Ogawa, Masaki Hanibuchi and Yasuhiko Nishioka : 血清Krebs von den Lungen-6 が高値を示した悪性胸膜中皮腫の1例, 第127回日本内科学会四国地方会, Dec. 2022.
32.	新居香織, Keiko Haji, Yu Aoi, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Hiroshi Kawano, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 関節炎を呈したACTH 単独欠損症の1例, 第127回日本内科学会四国地方会, Dec. 2022.
33.	森彩花, Keiko Haji, Yu Aoi, Kenya Miyamoto, Kojin Murakami, Yuki Tsukazaki, Hiroki Bandoh, Ryohiko Ozaki, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 免疫チェックポイント阻害薬使用後に肺胞出血をきたした1例, 第31回日本呼吸器内視鏡学会中国四国支部会, Dec. 2022.
34.	寺澤翠, Keiko Haji, 市原聖也, Yuya Yamashita, Asami Fukuya, Nobuhito Naito, Hiroto Yoneda, Kozo Kagawa, Hirokazu Ogino, Hiroshi Kawano, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 抗PD-L1抗体投与後に顕在化した抗ARS抗体陽性間質性肺炎の1例, 第67回日本呼吸器学会中国・四国地方会, Dec. 2022.
35.	中西颯斗, Keiko Haji, 松村有悟, Atsushi Mitsuhashi, 小川瑛, Takeshi Imakura, 美馬正人, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino, Satoshi Sakaguchi, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 同時に異なる3つの組織型を認めた多発性肺癌の1例, 第67回日本呼吸器学会中国・四国地方会, Dec. 2022.
36.	小路貴俊, Nobuhito Naito, Hiroshi Kawano, Kojin Murakami, Yuya Yamashita, 美馬正人, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 両側声帯麻痺を呈した多発血管炎性肉芽腫症に伴う肥厚性硬膜炎の1例, 第33回日本リウマチ学会中国・四国支部学術集会, Dec. 2022.
37.	Katsuhiro Atagi, Hiroshi Kawano, 小路貴俊, Kojin Murakami, Yuya Yamashita, 美馬正人, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 劇症1型糖尿病と同時期に発症した両側特発性外眼筋炎の1例, 第33回日本リウマチ学会中国・四国支部学術集会, Dec. 2022.
38.	小川瑛, Hiroshi Nokihara, Atsushi Mitsuhashi, 近藤健介, Yuki Tsukazaki, Yohhei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka : ALK融合遺伝子陽性非小細胞肺癌の効果予測因子に関する検討, 第63回日本肺癌学会学術集会, Dec. 2022.
39.	Na T. Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka : Eliminates MDSCs and enhances the efficacy of immune checkpoint inhibitor in thoracic tumors, The 63rd Annual Meeting of the Japan Lung Cancer Society, Dec. 2022.
40.	Hiroshi Nokihara, Hirokazu Ogino, Atsushi Mitsuhashi, 近藤健介, 小川瑛, Ryohiko Ozaki, Yohhei Yabuki, Hiroto Yoneda and Yasuhiko Nishioka : 胸水を伴うEGFR遺伝子変異陽性非小細胞肺がんに対するオシメルチニブの有効性の検討, 第63回日本肺癌学会学術集会, Dec. 2022.
41.	竹内栄治, 近藤健介, 岡野義夫, 市原聖也, Michihiro Kunishige, 門田直樹, 町田久典, 畠山暢生, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : 好酸球は免疫チェックポイント阻害薬治療を受けた非小細胞肺癌患者の予後予測バイオマーカー, 第63回日本肺癌学会学術集会, Dec. 2022.
42.	Ryohiko Ozaki, Hiroshi Nokihara, Yuki Tsukazaki, Yohhei Yabuki, Atsushi Mitsuhashi, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka : 間質性肺炎合併進展型小細胞肺癌における2次化学療法の有効性および安全性について, 第60回日本癌治療学会学術集会, Oct. 2022.
43.	Nobuhito Naito, 西村春佳, Yuya Yamashita, Kojin Murakami, Keiko Haji, Kazuya Koyama, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Masaki Hanibuchi and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスを用いたJAK阻害薬の抗線維化効果についての検討, 第50回日本臨床免疫学会総会, Oct. 2022.
44.	Atsushi Mitsuhashi, Hirokazu Ogino, Hiroshi Nokihara and Yasuhiko Nishioka : PD-1/PD-L1 blockade mediates antiangiogenic effects by tumorderived CXCL10/11 as a potential predictive biomarker, The 81st Annual Meeting of the Japanese Cancer Association, Sep. 2022.
45.	Atsushi Mitsuhashi, Hirokazu Ogino, Sugimoto Masamichi, Hiroshi Nokihara and Yasuhiko Nishioka : Fibrocyte drives antitumor immunity via T cell-costimulation in combination immunotherapy, The 81st Annual Meeting of the Japanese Cancer Association, Sep. 2022.
46.	Hirokazu Ogino, Atsuro Saijo and Yasuhiko Nishioka : Neoadjuvant vaccination with tumor-cell lysate induces CD8 T cell response in low-grade gliomas in randomized trial, The 81st Annual Meeting of the Japanese Cancer Association, Sep. 2022.
47.	中西颯斗, Keiko Haji, Yohhei Yabuki, 新居香織, 高丸利加子, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : セルペルカチニブが奏功したRET融合遺伝子陽性肺腺癌の1例, 第265回徳島医学会学術集会, Jul. 2022.
48.	Hirokazu Ogino, Taylor Jennie, Nejo Takahide, Gibson David, Watchmaker Payal, Atsuro Saijo, Tedesco Meghan, Rabbitt Jane, Olin Michael, Moertel Christopher, Salazar Andres, Molinaro Annette, Phillips Joanna, Butowski Nicholas, Clarke Jennifer, Theodosopoulos Philip, Chang Susan, Yasuhiko Nishioka, Berger Mitchel and Okada Hideho : Randomized trial of neoadjuvant vaccination with GBM6-AD tumor-cell lysate induces T cell response in low-grade gliomas, The 26th Annual Meeting of Japanese Association of Cancer Immunology, Jul. 2022.
49.	小倉佑一朗, Keiko Haji, 近藤健介, Kenji Otsuka, Hirokazu Ogino, Kazuya Koyama, 村上行人, Hiroki Bandoh, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 間質性肺炎への治療反応性から肝肺症候群の併存が顕在化した一例, 第66回日本呼吸器学会中国・四国地方会, Jul. 2022.
50.	松村有悟, Keiko Haji, 美馬正人, Yohhei Yabuki, Kenji Otsuka, Hiroto Yoneda, Hiroshi Nokihara, Hirokazu Ogino, Ryohiko Ozaki, 塚崎佑貴, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 小細胞肺癌への形質転換を認めたEGFR遺伝子変異陽性肺腺癌の3例, 第60回日本肺癌学会中国・四国支部学術集会, Jul. 2022.
51.	新居香織, Yohhei Yabuki, Keiko Haji, 高丸利加子, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : セルペルカチニブが奏効したRET融合遺伝子陽性肺腺癌の1例, 第60回日本肺癌学会中国・四国支部学術集会, Jul. 2022.
52.	Hirokazu Ogino, Atsuro Saijo and Yasuhiko Nishioka : 腫瘍ライセートを用いた術前がんワクチン療法は低悪性度神経膠腫におけるT細胞免疫応答を誘導する, 第26回日本がん分子標的治療学会学術集会, Jun. 2022.
53.	Atsushi Mitsuhashi, Hirokazu Ogino, Na Thi Nguyen, Hiroto Yoneda, Kenji Otsuka, 杉本正道, 根東攝, Hiroshi Nokihara and Yasuhiko Nishioka : 免疫チェックポイント阻害薬および血管新生阻害薬併用療法における腫瘍内fibrocyteの機能解析, 第26回日本がん分子標的治療学会学術集会, Jun. 2022.
54.	Hiroto Yoneda, Atsushi Mitsuhashi, Hirokazu Ogino, Ryohiko Ozaki, Yohhei Yabuki, Hiroshi Nokihara, Shinji Abe, 加藤幸成 and Yasuhiko Nishioka : 悪性胸膜中皮腫に対する抗ポドプラニン抗体および抗CTLA-4抗体による複合がん免疫療法の検討, 第26回日本がん分子標的治療学会学術集会, Jun. 2022.
55.	Keiko Haji, Yohhei Yabuki, 美馬正人, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : MET阻害薬が著効したMET遺伝子 exon14 skipping 変異陽性肺扁平上皮癌の1例, 第126回日本内科学会四国地方会, Jun. 2022.
56.	高橋啓輝, Yohhei Yabuki, 市原聖也, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 重度の嚥下障害を合併した抗Ro52抗体陽性皮膚筋炎の1例, 第126回日本内科学会四国地方会, Jun. 2022.
57.	Kojin Murakami, 原田紗希, Takeshi Imakura, Atsushi Mitsuhashi, 小川瑛, TSUKAZAKI Yuki, Ryohiko Ozaki, YABUKI Yohhei, Kozo Kagawa, Hiroto Yoneda, Akane Abe, Hirokazu Ogino, Kazuya Koyama, Seidai Satou, Satoshi Sakaguchi and Yasuhiko Nishioka : 抗GM-CSF抗体測定が早期診断に有用であった自己免疫性肺胞蛋白症の一例, 第45回日本呼吸器内視鏡学会学術集会, May 2022.
58.	Takeshi Imakura, Seidai Satou, 原田紗希, Atsushi Mitsuhashi, 小川瑛, Kojin Murakami, Yuki Tsukazaki, Ryohiko Ozaki, Yohhei Yabuki, Kozo Kagawa, Hiroto Yoneda, Akane Abe, Hirokazu Ogino, Satoshi Sakaguchi and Yasuhiko Nishioka : 肺門部・縦隔リンパ節腫大に対してEBUS-TBNAを実施し子宮頸癌再発と診断した1例, 第45回日本呼吸器内視鏡学会学術集会, May 2022.
59.	Ryohiko Ozaki, Hiroshi Nokihara, YABUKI Yohhei, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino and Yasuhiko Nishioka : Second-line chemotherapy for extensive-disease small cell lung cancer with interstitial lung disease, 第19回日本臨床腫瘍学会学術集会, Feb. 2022.
60.	Hirokazu Ogino, W Jennie Taylor, Nejo Takahide, David Gibson, B Payal Watchmaker, Megh Okada Atsuro Saijo Tadesco Kaori, Atsuro Saijo, Megh Tadesco, Jane Rabbitt, R Michael Olin, L Christopher Moertel, M Andres Salazar, Yasuhiko Nishioka, M Annette Molinaro, J Joanna Phillips, A Nicholas Butowski, L Jennifer Clarke, M Susan Chang, Mitchel Berger and Okada Hideho : Neoadjuvant vaccination with GBM6-AD, lysate of glioblastoma stem cell line, induces T-cell response in low-grade glioma, 第19回日本臨床腫瘍学会学術集会, Feb. 2022.
61.	石田卓也, Hiroshi Kawano, Takeshi Imakura, Kohjin Murakami, Yuya Yamashita, 美馬正人, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 当院における膠原病関連間質性肺疾患に対するニンテダニブの使用経験, 第32回日本リウマチ学会中国・四国支部学術集会, Dec. 2021.
62.	市原聖也, Hiroshi Kawano, Takeshi Imakura, Kohjin Murakami, Yuya Yamashita, 美馬正人, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 再発性多発軟骨炎治療中の不明熱精査でUBA1遺伝子解析により診断したVEXAS症候群の1例, 第32回日本リウマチ学会中国・四国支部学術集会, Dec. 2021.
63.	市原聖也, YABUKI Yohhei, Kohjin Murakami, Kozo Kagawa, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 亜急性に進行し，蜂巣肺様の所見を呈した薬剤性肺障害の1例, 第125回日本内科学会四国地方会, Dec. 2021.
64.	石田卓也, YABUKI Yohhei, Kozo Kagawa, Yuya Yamashita, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 成人Still病との鑑別を要した家族性地中海熱非典型例の1例, 第125回日本内科学会四国地方会, Dec. 2021.
65.	村上尚哉, YABUKI Yohhei, Ryohiko Ozaki, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : Sitafloxacinが奏効した肺Mycobacterium abscessus subsp. massiliense 症の1例, 第72回日本結核・非結核性抗酸菌症学会中国四国支部会, Dec. 2021.
66.	高丸利加子, YABUKI Yohhei, 磯村祐太, Kozo Kagawa, Kazuya Koyama, Kenji Otsuka, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 自然退縮を認めた気管支原発唾液腺型腫瘍の1例, 第30回日本呼吸器内視鏡学会中国四国支部会, Dec. 2021.
67.	小川瑛, YABUKI Yohhei, 青井優, Kozo Kagawa, Kazuya Koyama, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 両側肺に多発する斑状影を呈した自己免疫性肺胞蛋白症の1例, 第65回日本呼吸器学会中国・四国地方会, Dec. 2021.
68.	原田祥子, YABUKI Yohhei, 美馬正人, Ryohiko Ozaki, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 非結核性抗酸菌症との鑑別を要し，amikacin + minocyclineが奏効した肺ノカルジア, 第65回日本呼吸器学会中国・四国地方会, Dec. 2021.
69.	Atsushi Mitsuhashi, Hirokazu Ogino, Hiroto Yoneda, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka : 抗PD-1/PD-L1抗体による血管新生制御メカニズムの解析と治療効果予測バイオマーカーとしての応用, 第62回日本肺癌学会学術集会, Nov. 2021.
70.	Ryohiko Ozaki, Hiroshi Nokihara, Atsushi Mitsuhashi, 近藤健介, YABUKI Yohhei, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka : 間質性肺炎合併小細胞肺癌に対する二次化学療法の有効性及び安全性の検討, 第62回日本肺癌学会学術集会, Nov. 2021.
71.	Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, YABUKI Yohhei, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka : 悪性胸膜中皮腫患者におけるニボルマブの免疫関連有害事象と治療効果の相関性, 第59回日本癌治療学会学術集会, Oct. 2021.
72.	Kenji Otsuka, Atsushi Mitsuhashi, Ryohiko Ozaki, YABUKI Yohhei, Hiroto Yoneda, Hirokazu Ogino, Hiroshi Nokihara, 竹内栄治, 杉浦八十生, 知花賢治, 田村厚久, 安宅信二 and Yasuhiko Nishioka : 進展型小細胞肺癌における予後規定因子, 第59回日本癌治療学会学術集会, Oct. 2021.
73.	Atsushi Mitsuhashi, Hirokazu Ogino, Atsuro Saijo, Kenji Otsuka, 杉本正道, Hiroshi Nokihara and Yasuhiko Nishioka : 免疫チェックポイント阻害薬および血管新生阻害薬併用療法におけるfibrocyteの役割, 第80回日本癌学会学術総会, Oct. 2021.
74.	Satoshi Sakaguchi, YABUKI Yohhei, Takeshi Imakura, Hiroto Yoneda, Kohjin Murakami, Kazuya Koyama, Kozo Kagawa, 小川瑛, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 索状の小葉間隔壁の肥厚を認め胸腔鏡下肺生検にて診断した間質性肺炎の1例, 第63回日本呼吸器学会中国・四国地方会, Aug. 2021.
75.	中内友合江, YABUKI Yohhei, Keiko Haji, Hiroto Yoneda, Atsushi Mitsuhashi, 青井優, 石田卓也, 村上尚哉, Hirokazu Ogino, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : Tepotinibが著効したMET遺伝子exon14 skipping変異陽性肺腺癌の1例, 第59回日本肺癌学会中国・四国支部学術集会, Aug. 2021.
76.	市原聖也, YABUKI Yohhei, Ryohiko Ozaki, 近藤健介, Hiroto Yoneda, Kenji Otsuka, Asami Fukuya, 高丸利加子, 原田祥子, Hirokazu Ogino, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : AtezolizumabのImmune-Related Adverse Eventによる急性腎障害を認めた非小細胞肺癌の1例, 第59回日本肺癌学会中国・四国支部学術集会, Aug. 2021.
77.	Atsushi Mitsuhashi, Hirokazu Ogino, Hiroto Yoneda, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka : 肺がん肝転移におけるspheroid形成がん幹細胞様分画の役割, 第30回日本がん転移学会学術集会・総会, Jul. 2021.
78.	Atsushi Mitsuhashi, Tania Afroj, Na Thi Nguyen, Hirokazu Ogino, Hiroto Yoneda, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka : 抗PD-1/PD-L1抗体による腫瘍血管新生抑制メカニズムの解析と治療効果予測バイオマーカーとしての応用., 第25回日本がん分子標的治療学会学術集会, May 2021.
79.	Tania Afroj, Hirokazu Ogino, Atsushi Mitsuhashi, Hiroto Yoneda, Hiroyuki Kozai, Kenji Otsuka, Hiroshi Nokihara, Masahiro Abe and Yasuhiko Nishioka : 腫瘍免疫における線維細胞の免疫調節機能の検討, 第24回日本がん分子標的治療学会学術集会, Oct. 2020.
80.	Atsushi Mitsuhashi, Tania Afroj, Hirokazu Ogino, NGUYEN NA THI, Hiroto Yoneda, Hiroyuki Kozai, Kenji Otsuka, 杉本正道, 根東攝, Hiroshi Nokihara and Yasuhiko Nishioka : 免疫チェックポイント阻害薬および血管新生阻害薬併用療法における腫瘍内 fibrocyte-like cell の機能解析, 第24回日本がん分子標的治療学会学術集会, Oct. 2020.
81.	Atsushi Mitsuhashi, Hirokazu Ogino, Atsuro Saijo, Kenji Otsuka, 杉本正道, Hiroshi Nokihara and Yasuhiko Nishioka : 免疫チェックポイント阻害薬および血管新生阻害薬併用療法における腫瘍内 fibrocyte-like cell の機能解析, 第79回日本癌学会学術総会, Oct. 2020.
82.	Atsushi Mitsuhashi, Hirokazu Ogino, 木宿昌俊, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka : 免疫チェックポイント阻害薬および血管新生阻害薬による複合がん免疫療法における腫瘍内fibrocytelike cellの機能解析, 第32回日本バイオセラピィ学会学術集会総会, Nov. 2019.
83.	Kenji Otsuka, Hiroto Yoneda, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Makoto Tobiume, Hiroshi Nokihara and Yasuhiko Nishioka : 間質性肺炎合併非小細胞肺癌における2次化学療法の安全性と有効性の検討, 第57回日本癌治療学会学術集会, Oct. 2019.
84.	石田卓也, Kozo Kagawa, Hiroto Yoneda, 坂東紀子, Nobuhito Naito, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Kenji Nishimura, 山本遥平, Yuko Toyoda, Hiroshi Nokihara and Yasuhiko Nishioka : 顕微鏡的多発血管炎の治療中に重症筋無力症クリーゼを発症した1例, 第259回徳島医学会学術集会, Aug. 2019.
85.	安宅克博, Kozo Kagawa, Mayo Kondou, Seidai Satou, Hiroto Yoneda, Hirokazu Ogino, Makoto Tobiume, Hiroyuki Kozai, Kenji Otsuka, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : Nivolumab投与により腹水の著明な減少を認めた悪性胸膜中皮腫の1例, 第58回日本肺癌学会中国・四国支部学術集会, Jul. 2019.
86.	近藤圭大, Kozo Kagawa, Mayo Kondou, Hirokazu Ogino, Makoto Tobiume, Hiroto Yoneda, Kenji Otsuka, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : 当科における局所進行非小細胞肺癌患者に対する化学放射線療法後のDurvalumabによる治療の臨床的検討, 第58回日本肺癌学会中国・四国支部学術集会, Jul. 2019.
87.	Kenji Otsuka, Hisatsugu Goto, Masaki Hanibuchi, Hirokazu Ogino, Atsuro Saijo, Hiroyuki Kozai, Hiroto Yoneda, Makoto Tobiume and Yasuhiko Nishioka : 化学療法は腫瘍内の骨髄由来抑制細胞を減少させることにより抗PD-1抗体の抗腫瘍効果を増強する, 第28回日本がん転移学会学術集会・総会, Jul. 2019.
88.	西村春佳, Hiroto Yoneda, Kozo Kagawa, 小山壱也, Makoto Tobiume, Hirokazu Ogino, Atsuro Saijo, 宮本憲哉, 原田紗希, 坂東紀子, Yuko Toyoda and Yasuhiko Nishioka : 癌性リンパ管症の診断にBAL が有用であった多発すりガラス陰影を呈した肺腺癌の1 例, 第42回日本呼吸器内視鏡学会学術集会, Jul. 2019.
89.	Hiroto Yoneda, 西村春佳, Kozo Kagawa, Makoto Tobiume, Hirokazu Ogino, 小山壱也, Atsuro Saijo, Yuko Toyoda and Yasuhiko Nishioka : 気管支鏡検査にて診断し得たリンパ脈管筋腫症の1 例, 第42回日本呼吸器内視鏡学会学術集会, Jul. 2019.
90.	Yasuhiko Nishioka, Hirokazu Ogino and Atsushi Mitsuhashi : 血管新生阻害薬耐性とその克服, 第23回日本がん分子標的治療学会学術集会(シンポジウム), Jun. 2019.
91.	Atsuro Saijo, Hisatsugu Goto, Hiroyuki Kozai, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka : 非小細胞肺がんに合併した悪性胸水に対するbevacizumabの有効性と耐性化機序の解析, 第23回日本がん分子標的治療学会学術集会, Jun. 2019.
92.	Atsushi Mitsuhashi, Hisatsugu Goto, Hirokazu Ogino, Kenji Otsuka, 杉本正道, 根東攝 and Yasuhiko Nishioka : 免疫チェックポイント阻害薬および血管新生阻害薬併用療法における fibrocyte-like cell の機能解析, 第23回日本がん分子標的治療学会学術集会, Jun. 2019.
93.	Asami Fukuya, Yuko Toyoda, Hirokazu Ogino, Hiroshi Kawano, Hisatsugu Goto, Hiroshi Nokihara, Masahiko Azuma and Yasuhiko Nishioka : Stevens-Johnson症候群後に合併した閉塞性細気管支炎にステロイドおよびタクロリムスが有効であった1例, 第6回日本呼吸ケア・リハビリテーション学会中国・四国支部学術集会, Jun. 2019.
94.	Atsushi Mitsuhashi, Makoto Tobiume, Hirokazu Ogino, Mayo Kondou, Yuko Toyoda, Hisatsugu Goto, Mitsuteru Yoshida, Hirohisa Ogawa, Hiroshi Nokihara and Yasuhiko Nishioka : 肺多形癌における上皮間葉転換 (EMT)の検討, 第120回日本内科学会四国地方会, May 2019.
95.	髙橋直希, Nobuhito Naito, Mayo Kondou, Hirokazu Ogino, Hiroshi Kawano, Yuko Toyoda, Hirokazu Miki, Masahiko Azuma, Hiroshi Nokihara and Yasuhiko Nishioka : 治療抵抗性のSLEに伴う赤芽球癆にシクロホスファミドパルス療法が著効した1例, 第120回日本内科学会四国地方会, May 2019.
96.	Nobuhito Naito, Hiroshi Kawano, Mayo Kondou, Hirokazu Ogino, Seidai Satou, Yuko Toyoda, Hisatsugu Goto and Yasuhiko Nishioka : 間質性肺炎合併関節リウマチに対するJAK阻害薬の使用経験, 第63回日本リウマチ学会総会・学術集会, Apr. 2019.
97.	Afroj Tania, Hirokazu Ogino, Makoto Tobiume, Hiroto Yoneda, Kisyuku Masatoshi, Atsuro Saijo, Atsushi Mitsuhashi, Koyama Kazuya, Hisatsugu Goto and Yasuhiko Nishioka : Analyses of immuno-modulatory function of fibrocytes in tumor immunity, The 59th Annual Meeting of the Japanese Respiratory Society, Apr. 2019.
98.	原田紗希, Mayo Kondou, 西村春佳, Nobuhito Naito, Hiroshi Kawano, Yusuke Osaki, Yoshimi Bando, Naoki Takahashi, Kozo Kagawa, Yasuhiko Nishioka, Hirokazu Ogino, Makoto Tobiume, Atsuro Saijo, Hiroshi Nokihara, Yuko Toyoda, Masahiko Azuma, Hisatsugu Goto, Hisanori Uehara and Yasuhiko Nishioka : 傍腫瘍性神経症候群を合併した小細胞肺癌の一例, 第60回日本呼吸器学会中国・四国地方会, Dec. 2018.
99.	Hiroki Bandoh, Mayo Kondou, Ryo Miyagi, Hirokazu Ogino, Makoto Tobiume, Takeshi Oya, Hirohisa Ogawa, Hiroshi Kawano, Yuko Toyoda, Hiroshi Nokihara, Masahiko Azuma, Hisatsugu Goto, Koichi Sairyo and Yasuhiko Nishioka : エイの刺創後に発症した皮膚Mycobacterium massiliense症の一例, 第69回日本結核病学会中国四国支部会, Dec. 2018.
100.	Hirokazu Ogino, Kenji Otsuka, Atsushi Mitsuhashi, 木宿昌俊 and Yasuhiko Nishioka : 肺癌・悪性胸膜中皮腫マウスモデルを用いた免疫チェックポイント阻害薬と化学療法の併用効果に関する検討, 第31回日本バイオセラピィ学会学術集会総会, Dec. 2018.
101.	宮本憲哉, Mayo Kondou, Nobuhito Naitoh, Hiroki Yamazaki, Yuko Toyoda, Hirokazu Ogino, Hiroshi Kawano, Hisatsugu Goto, Ryuji Kaji and Yasuhiko Nishioka : 免疫介在性壊死性ミオパチーの1例, 第119回日本内科学会四国地方会, Dec. 2018.
102.	Yohsuke Kaneko, Mayo Kondou, Naoki Takahashi, Makoto Tobiume, Hirokazu Ogino, Seidai Satou, Hirokazu Miki, Hisatsugu Goto, Masahiro Abe and Yasuhiko Nishioka : 多発小結節影を認めたHIV陽性ニューモシスチス肺炎の1例, 第119回日本内科学会四国地方会, Dec. 2018.
103.	Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Atsuro Saijo, Hisatsugu Goto, Hiroshi Nokihara and Yasuhiko Nishioka : 間質性肺炎合併非小細胞肺癌に対する 2 次化学療法の検討, 第59回日本肺癌学会学術集会, Dec. 2018.
104.	Yuya Yamashita, Hiroshi Kawano, Takeshi Imakura, Nobuhito Naito, Mayo Kondou, Hirokazu Ogino, Seidai Satou, Yuko Toyoda, 後東久嗣 and Yasuhiko Nishioka : TAFRO症候群の1例, 第29回日本リウマチ学会中国・四国支部学術集会, Dec. 2018.
105.	Atsuro Saijo, Hiroyuki Kozai, 近藤健介, Hisatsugu Goto, Hirokazu Ogino, Hiroshi Nokihara, Yuko Toyoda and Yasuhiko Nishioka : 非小細胞肺がんに対する免疫チェックポイント阻害剤の生存期間に関する予後不良因子の検討, 第59回日本肺癌学会学術集会, Nov. 2018.
106.	Nobuhito Naitoh, Hiroshi Kawano, Mayo Kondou, Hirokazu Ogino, Seidai Satou, Yuko Toyoda, Hisatsugu Goto and Yasuhiko Nishioka : EBウイルス再活性化を反復した高疾患活動性関節リウマチに対してアバタセプトが有効であった1例, 第29回日本リウマチ学会中国・四国支部学術集会, Nov. 2018.
107.	Hiroto Yoneda, Hirokazu Ogino, Yuko Toyoda, Hiroshi Kawano, Kenji Ohtsuka, Atsuro Saijo, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : 高齢肺癌患者の若年者と比較した臨床的特徴, 第56回日本癌治療学会学術集会, Oct. 2018.
108.	Naoki Takahashi, Hirokazu Ogino, Masaki Hanibuchi, Atsuro Saijo, Makoto Tobiume, Hiroyuki Kozai, Hiroto Yoneda, Asami Fukuya, Atsushi Mitsuhashi, 宮本憲哉, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : 当科における高齢者肺癌の臨床的検討, 第257回徳島医学会学術集会, Aug. 2018.
109.	Hirokazu Ogino, Masaki Hanibuchi, Souji Kakiuchi, 安宅信二, 大串文隆, 清水英治, 葉久貴司, Kenji Ohtsuka, Atsuro Saijo, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : 間質性肺炎合併未治療進行非小細胞肺癌に対するTS-1+CBDCA併用療法の第Ⅱ相臨床試験, 第16回日本臨床腫瘍学会学術集会, Jul. 2018.
110.	Atsuro Saijo, Hisatsugu Goto, Hiroyuki Kozai, Makoto Tobiume, Hirokazu Ogino, Hiroto Yoneda and Yasuhiko Nishioka : 肺がんの悪性胸水に対する bevacizumab の有効性と耐性化機序の解析, 第27回日本がん転移学会学術集会・総会, Jul. 2018.
111.	Atsushi Mitsuhashi, Kozo Kagawa, Hiroto Yoneda, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, Mayo Kondou, Naoki Takahashi, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : 当科における免疫チェックポイント阻害薬による薬剤性間質性肺疾患の検討, 第59回日本呼吸器学会中国・四国地方会/第57回日本肺癌学会中国・四国支部学術集会, Jul. 2018.
112.	森文香, Hiroto Yoneda, Mayo Kondou, Hirokazu Ogino, Makoto Tobiume, Atsuro Saijo, Asami Fukuya, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : 複視を発症し，斜台部腫瘍を契機に診断された非小細胞肺癌の1例, 第57回日本肺癌学会中国・四国支部学術集会, Jul. 2018.
113.	多幡有莉乃, Hirokazu Ogino, Atsuro Saijo, Hiroyuki Kozai, Mayo Kondou, Yoshimi Bando, 松本大資, Hisatsugu Goto, Hiromitsu Takizawa and Yasuhiko Nishioka : 悪性胸水を契機に診断された放射線誘発血管肉腫の1例, 第59回日本呼吸器学会中国・四国地方会, Jul. 2018.
114.	Hiroto Yoneda, Hirokazu Ogino, Hiroyuki Kozai, Kenji Otsuka, Makoto Tobiume, Atsuro Saijo, Yuko Toyoda, Hisatsugu Goto, Hiroshi Nokihara and Yasuhiko Nishioka : 当科における Pembrolizumab の使用経験, 第118回日本内科学会四国地方会, Jun. 2018.
115.	美馬正人, Hirokazu Ogino, Mayo Kondou, Hiroyuki Kozai, Kenji Otsuka, 小山壱也, Yuko Toyoda, Masahiko Azuma, Hisatsugu Goto and Yasuhiko Nishioka : 特発性肺骨化症の2例, 第118回日本内科学会四国地方会, Jun. 2018.
116.	宮本綾香, Hiroyuki Kozai, Hirokazu Ogino, Mayo Kondou, Kenji Otsuka, 小山壱也, Yuko Toyoda, Masahiko Azuma and Yasuhiko Nishioka : 肺M.chelonae 症の経過中に診断された肺M.massiliense 症の1例, 第118回日本内科学会四国地方会, Jun. 2018.
117.	Yuko Toyoda, 小山壱也, 西村春佳, Kohzoh Kagawa, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, Hiroto Yoneda and Yasuhiko Nishioka : 乳癌患者の放射線治療後に発症した放射線肺炎における気管支肺胞洗浄液の臨床的検討, 第41回日本呼吸器内視鏡学会学術集会, May 2018.
118.	Kohzoh Kagawa, Yuko Toyoda, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, Hiroto Yoneda, 小山壱也, 西村春佳 and Yasuhiko Nishioka : EBUS-TBNA後に縦隔炎を発症した症例における危険因子の検討, 第41回日本呼吸器内視鏡学会学術集会, May 2018.
119.	Hirokazu Ogino, Hisatsugu Goto, Kenji Ohtsuka, Atsuro Saijo, Masaki Hanibuchi and Yasuhiko Nishioka : 線維細胞が腫瘍免疫に及ぼす影響についての検討, 第22回日本がん分子標的治療学会学術集会, May 2018.
120.	Kenji Ohtsuka, Hisatsugu Goto, Hirokazu Ogino, Atsuro Saijo, Masaki Hanibuchi and Yasuhiko Nishioka : 肺癌・悪性胸膜中皮腫マウスモデルにおける免疫チェックポイント阻害薬と化学療法の併用効果, 第22回日本がん分子標的治療学会学術集会, May 2018.
121.	Makoto Tobiume, Hirokazu Ogino, Afroj Tania, Hisatsugu Goto, Hiroshi Nokihara, Mitsuteru Yoshida, Yukikiyo Kawakami, Hiromitsu Takizawa, Hirohisa Ogawa, Koichi Tsuneyama and Yasuhiko Nishioka : 上皮間葉転換 (EMT)が肺多形癌の悪性化に寄与する可能性についての検討., 第58回日本呼吸器学会学術講演会, Apr. 2018.
122.	Nobuhito Naitoh, Hiroshi Kawano, 山下雄也, Mayo Kondoh, Hirokazu Ogino, Yuko Toyoda, Jun Kishi, Hisatsugu Goto and Yasuhiko Nishioka : アザチオプリン併用療法が有効であった間質性肺炎合併抗MDA5抗体陽性皮膚筋炎の3例．, 第62回日本リウマチ学会総会・学術集会, Apr. 2018.
123.	Hirokazu Ogino, Masaki Hanibuchi, Atsuro Saijo, Kenji Ohtsuka, Yuko Toyoda, Hisatsugu Goto and Yasuhiko Nishioka : 徳島大学病院の肺癌症例において高齢者と若年者を比較した後ろ向き研究．, 第115回日本内科学会総会・講演会, Apr. 2018.
124.	Hiroto Yoneda, Kenji Ohtsuka, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, Hiroyuki Kozai, Yuko Toyoda, Hisatsugu Goto, Hiroshi Nokihara and Yasuhiko Nishioka : 当科におけるnivolumabの有害事象の検討, 第117回日本内科学会四国地方会, Dec. 2017.
125.	山下雄也, Hiroshi Kawano, Jun Kishi, Nobuhito Naitoh, Hirokazu Ogino, Mayo Kondoh, Shun Morizumi, Yuko Toyoda, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka : 全身性強皮症を背景にposterior reversible encephalopathy syndromeを発症した一例, 第28回日本リウマチ学会中国・四国支部学術集会, Nov. 2017.
126.	今倉健, Nobuhito Naitoh, 山下雄也, Hirokazu Ogino, Jun Kishi, Hiroshi Kawano, Mayo Kondoh, Shun Morizumi, Yuko Toyoda, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka : ループス心筋炎の2例, 第28回日本リウマチ学会中国・四国支部学術集会, Nov. 2017.
127.	Hirokazu Ogino, Yuko Toyoda, Hiroshi Kawano, Jun Kishi, Mayo Kondoh, Shun Morizumi, 山下雄也, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka : 当院における肺病変合併全身性エリテマトーデス症例の臨床的検討, 第28回日本リウマチ学会中国・四国支部学術集会, Nov. 2017.
128.	鈴江涼子, Haruka Nishimura, Hirokazu Ogino, Kenji Ohtsuka, Makoto Tobiume, Hiroshi Kawano, Asami Fukuya, 山下雄也, Hisatsugu Goto and Yasuhiko Nishioka : 心タンポナーデをきたした結核性心膜炎の1例, 第68回日本結核病学会中国四国支部会, Oct. 2017.
129.	Makoto Tobiume, Shun Morizumi, 鈴江涼子, Tetsuya Hida, Hirokazu Ogino, Kenji Ohtsuka, Hisatsugu Goto, Hisanori Uehara, Yoshiaki Kubo and Yasuhiko Nishioka : BRAF 陽性肺原発悪性黒色腫の1例, 第58回日本呼吸器学会中国・四国地方会, Oct. 2017.
130.	Atsuro Saijo, Masaki Hanibuchi, Hirokazu Ogino, Hiroshi Nokihara, Yuko Toyoda, Hisatsugu Goto and Yasuhiko Nishioka : 再発小細胞肺癌に対するpaclitaxel療法の検討, 第58回日本肺癌学会学術集会, Oct. 2017.
131.	Atsuro Saijo, Hisatsugu Goto, Hirokazu Ogino, Hiroshi Nokihara and Yasuhiko Nishioka : 骨髄由来線維細胞(fibrocyte)は肺癌のがん幹細胞様特性を促進する, 第76回日本癌学会学術総会, Sep. 2017.
132.	山下貴央, Haruka Nishimura, Hirokazu Ogino, Kenji Ohtsuka, Makoto Tobiume, Yuko Toyoda, Hisatsugu Goto and Yasuhiko Nishioka : 心タンポナーデをきたした結核性心膜炎の1例, 第255回徳島医学会学術集会, Aug. 2017.
133.	大西一, Shun Morizumi, Tetsuya Hida, Yoshihiro Matsudate, Hirokazu Ogino, Kenji Ohtsuka, Makoto Tobiume, Hisatsugu Goto, Hisanori Uehara, Yoshiaki Kubo and Yasuhiko Nishioka : BRAF陽性肺原発悪性黒色腫の1例, 第255回徳島医学会学術集会, Aug. 2017.
134.	Hirokazu Ogino, Masaki Hanibuchi, Atsuro Saijo, Toshifumi Tezuka, Hisatsugu Goto and Yasuhiko Nishioka : 徳島大学病院における高齢者肺癌と若年者肺癌の臨床的特徴に関する比較検討, 第15回日本臨床腫瘍学会学術集会, Jul. 2017.
135.	Atsuro Saijo, Hirokazu Ogino, Kenji Ohtsuka, Toshifumi Tezuka, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : Clinical efficacy of bevacizumab for non-squamous non-small cell lung cancer patients with malignant pleural effusion., 第15回日本臨床腫瘍学会学術集会, Jul. 2017.
136.	喜田有佳里, Kohzoh Kagawa, Kenji Ootsuka, Hirokazu Ogino, Makoto Tobiume, Atsuro Saijo, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : 放射線治療のアブスコパル効果によると考えられる腫瘍縮小を認めた肺癌の1例, 第56回日本肺癌学会中国・四国支部学術集会., Jul. 2017.
137.	今倉健, Kenji Ohtsuka, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, Hiroyuki Kozai, Hisatsugu Goto, Hiroshi Nokihara and Yasuhiko Nishioka : 小細胞肺癌への転化を認めたEGFR遺伝子変異陽性肺腺癌の1例, 第56回日本肺癌学会中国・四国支部学術集会, Jul. 2017.
138.	Toshihiro Izumi, Shinji Abe, Hirokazu Ogino, Hisatsugu Goto, Masaki Hanibuchi, 加藤幸成 and Yasuhiko Nishioka : 悪性胸膜中皮腫同所移植マウスモデルに対する新規マウス抗ポドプラニン抗体LpMab-21による抗腫瘍効果の検討, 第21回日本がん分子標的学会学術集会, Jun. 2017.
139.	Hirokazu Ogino, Masaki Hanibuchi, Souji Kakiuchi, Atsuro Saijo, Toshifumi Tezuka, Yuko Toyoda, Satoshi Sakaguchi, Hisatsugu Goto, Kokichi Arisawa and Yasuhiko Nishioka : Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital., The 57th Annual Meeting of the Japanese Respiratory Society, Apr. 2017.
140.	Atsuro Saijo, Hisatsugu Goto, Mayuri Nakano, Mitsuhashi Atsushi, Hirokazu Ogino, Makoto Tobiume, Kenji Ohtsuka, Hiroto Yoneda, Masaki Hanibuchi and Yasuhiko Nishioka : Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells., The 57th Annual Meeting of the Japanese Respiratory Society, Apr. 2017.
141.	Shun Morizumi, Seidai Satou, Hirokazu Ogino, Koyama Kazuya, Haruka Nishimura, Yuko Toyoda, Hiroshi Kawano and Yasuhiko Nishioka : Inhibition of pan-fibroblast growth factor receptor signaling in bleomycin-induced pulmonary fibrosis in mice, The 57th Annual Meeting of the Japanese Respiratory Society, Apr. 2017.
142.	菊地高史, Toshifumi Tezuka, 近藤真代, Hirokazu Ogino, Hiroshi Kawano, Hisatsugu Goto, Jun Kishi, Masahiko Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : Stevens-Johnson 症候群後に発症した閉塞性細気管支炎にステロイドおよびタクロリムスが有効であった1例, 第56回日本呼吸器学会中国・四国地方会.岡山.2016年12月23, Dec. 2016.
143.	Masaki Hanibuchi, Toshifumi Tezuka, Atsuro Saijo, Hirokazu Ogino, Hisatsugu Goto and Yasuhiko Nishioka : 当科における高齢者肺癌の若年者との比較検討, 第57回日本肺癌学会学術集会, Dec. 2016.
144.	Hirokazu Ogino, Hisatsugu Goto, Atsuro Saijo, Souji Kakiuchi, Masaki Hanibuchi and Yasuhiko Nishioka : 徳島大学病院における進展型小細胞肺癌患者の予後因子に関する後ろ向き研究, 第57回日本肺癌学会学術集会, Dec. 2016.
145.	Atsuro Saijo, Toshifumi Tezuka, Hirokazu Ogino, Yuko Toyoda, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 悪性胸水を伴った非扁平上皮非小細胞肺癌に対する Bevacizumab 併用化学療法の検討, 第57回日本肺癌学会学術集会, Dec. 2016.
146.	Yuko Toyoda, 山下雄也, Shun Morizumi, Mayo Kondoh, Hirokazu Ogino, Hiroshi Kawano, Toshifumi Tezuka, Jun Kishi, Hisatsugu Goto, Masaki Hanibuchi, Masaki Hanibuchi and Yasuhiko Nishioka : 当院における膠原病関連間質性肺炎の急性憎悪の臨床的検討, 第27回日本リウマチ学会中国・四国支部学術集会, Dec. 2016.
147.	Hirokazu Ogino, Jun Kishi, Hiroshi Kawano, Toshifumi Tezuka, Yuko Toyoda, Hisatsugu Goto, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 関節リウマチの薬物療法における栄養状態の変化の検討, 第27回日本リウマチ学会中国・四国支部学術集会, Dec. 2016.
148.	山下雄也, Yuko Toyoda, Hirokazu Ogino, Hiroshi Kawano, Toshifumi Tezuka, Jun Kishi, Hisatsugu Goto, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 当院におけるループス腎炎に対するIVCYとMMFの治療経験, 第27回日本リウマチ学会中国・四国支部学術集会, Dec. 2016.
149.	田中こころ, Hirokazu Ogino, Jun-ya Miyata, 山下雄也, Shun Morizumi, Mayo Kondoh, Hiroshi Kawano, Toshifumi Tezuka, Yuko Toyoda, Jun Kishi, Hisatsugu Goto, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 15年前より認める慢性腎機能障害に対してステロイド加療が奏功した腎サルコイドーシスの1例, 第27回日本リウマチ学会中国・四国支部学術集会, Dec. 2016.
150.	Hirokazu Ogino, Masaki Hanibuchi, 大塚憲司, Atsuro Saijo, Satoshi Sakaguchi, Toshifumi Tezuka, Souji Kakiuchi, Hisatsugu Goto and Yasuhiko Nishioka : 徳島大学病院における進展型小細胞肺癌患者の予後因子についての検討, 第14回日本臨床腫瘍学会学術集会, Jul. 2016.
151.	山本清成, Toshifumi Tezuka, Hirokazu Ogino, Hisatsugu Goto, Jun Kishi, Masahiko Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : 下顎歯肉癌治療後に発生した放射線誘発血管肉腫の1例, 第253回徳島医学会学術集会, Jul. 2016.
152.	Hirokazu Ogino, Hisatsugu Goto, Atsuro Saijo, 大塚憲司, Masaki Hanibuchi and Yasuhiko Nishioka : 受容体チロシンキナーゼROR2は悪性胸膜中皮腫細胞の増殖を制御する, 第25回日本がん転移学会学術集会・総会, Jul. 2016.
153.	Atsuro Saijo, Hisatsugu Goto, 三橋惇志, Mayuri Nakano, 大塚憲司, Hirokazu Ogino, Satoshi Sakaguchi, Masaki Hanibuchi and Yasuhiko Nishioka : 骨髄由来線維細胞(fibrocyte)は肺癌のがん幹細胞様特性を促進する, 第25回日本がん転移学会学術集会・総会, Jul. 2016.
154.	森住俊, Seidai Satou, Hirokazu Ogino, Hiroshi Kawano, Satoshi Sakaguchi, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 当院におけるニンテダニブの特発性肺線維症に対する使用経験, 第114回日本内科学会四国地方会, May 2016.
155.	猪子未希, Hirokazu Ogino, Mayuri Nakano, 岡崎弘泰, 大塚憲司, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi, Yoshimi Bando, Koichi Tsuneyama and Yasuhiko Nishioka : 脳，口蓋垂，喉頭および小腸への遠隔転移を形成する稀な臨床経過をたどった右上葉原発多形癌の一剖検例, 第54回日本呼吸器学会中国・四国地方会, Dec. 2015.
156.	Hiroto Yoneda, Seidai Satou, Kohzoh Kagawa, Hirokazu Ogino, Satoshi Sakaguchi, Yuko Toyoda, Momoyo Azuma, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : 骨髄異形成症候群に播種性結核症を合併し治療に難渋した一例, 第66回日本結核病学会中国四国支部会, Dec. 2015.
157.	Shun Morizumi, Seidai Satou, Hirokazu Ogino, Mayo Kondoh, Toshifumi Tezuka, Yuko Toyoda, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : 当科で施行された胸膜癒着術におけるタルク製剤とOK-432の使用成績の比較, 第113回日本内科学会四国地方会, Dec. 2015.
158.	山下雄也, Hirokazu Ogino, Jun Kishi, Yuko Toyoda, Shun Morizumi, Mayo Kondoh, Terumi Takikura, Seidai Satou, Hiroshi Kawano, Toshifumi Tezuka, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 強膜炎，ネフローゼ症候群および僧房弁腱索断裂による重症僧房弁閉鎖不全症を呈した全身性エリテマトーデスの1例, 第26回日本リウマチ学会中国・四国支部学術集会, Dec. 2015.
159.	Hirokazu Ogino, 三橋惇志, Hisatsugu Goto, Atsuro Saijo, Seidai Satou, Satoshi Sakaguchi, Toshifumi Tezuka, 倉本卓哉, 田畑祥, Hisanori Uehara, Masaki Hanibuchi and Yasuhiko Nishioka : Sphere形成癌幹細胞様分画のヒト肺癌多臓器転移モデルマウスにおける役割についての解析, 第74回日本癌学会学術総会, Oct. 2015.
160.	猪子未希, Hirokazu Ogino, Satoshi Sakaguchi, 岸昌美, Yuko Toyoda, 近藤真代, Mayuri Nakano, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : Nocardia wallacei感染症の1例, 第53回日本呼吸器学会中国・四国地方会, Jul. 2015.
161.	Souji Kakiuchi, Hirokazu Ogino, Kenji Otsuka, Satoshi Sakaguchi, Atsuro Saijo, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 当科における間質性肺炎合併肺癌の治療の現状, 第55回日本呼吸器学会学術講演会, Apr. 2015.
162.	Maiko Iwasaka, Seidai Satou, Hirokazu Ogino, Satoshi Sakaguchi, Yuko Toyoda, Mayuri Nakano, Shun Morizumi, Hirohisa Ogawa, Souji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : Idiopathic pleuroparenchymal fibroelastosis (IPPFE) における間質性肺炎マーカーの検討, 第112回日本内科学会講演会, Apr. 2015.

Et cetera, Workshop:

1.	宮本翔子, 遠藤理子, 佐藤有莉乃, Hiromichi Kawashima, Kazutoshi Murao, Yoshiaki Kubo and Hirokazu Ogino : 抗PD-L1抗体投与中に発症した表皮の全層壊死を伴う苔癬様皮疹の1例, 第14回日本臨床皮膚科医会四国ブロック, Jul. 2023.
2.	宮本翔子, 遠藤理子, 佐藤有莉乃, Hiromichi Kawashima, Kazutoshi Murao, Yoshiaki Kubo and Hirokazu Ogino : 抗PD-L1抗体投与中に生じた表皮の全層性壊死を伴う苔癬様皮疹の1例, 第158回日本皮膚科学会徳島地方会, May 2023.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

ヘパラナーゼ制御によるhot tumor誘導と新規がん複合免疫療法の創出 (Project/Area Number: 24K10287 )
腫瘍内線維細胞における時計遺伝子の機能解析と新規複合がん免疫療法開発への応用 (Project/Area Number: 23K06637 )
肺がん・中皮腫における新たな抗原提示細胞の同定から革新的複合がん免疫療法への展開 (Project/Area Number: 23K24340 )
腫瘍内免疫療法を用いた新規複合がん免疫療法の効果規定因子を同定する試み (Project/Area Number: 22K07304 )
Analyses of the immuno-modulatory function of fibrocytes in tumor immunity (Project/Area Number: 17K16046 )
The fibrocyte research for clarifying and overcoming the resistance against anti-angiogenesis therapy in lung cancer (Project/Area Number: 17K09657 )
Novel target cells in tumor microenvironment of lung cancer: focusing on fibrocytes to overcome drug resistance and develop the innovative therapy (Project/Area Number: 16H05309 )
The role of cancer stem cell-like sphere forming cells in multi-organ metastasis of lung cancer (Project/Area Number: 15K19420 )
Search by Researcher Number (20745294)

Associate Professor : Ogino, Hirokazu

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)